[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHBphZRTuBZ5m6pwVTt9T0t8I5ppslmsM4TFa3kKh4Xo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University of Oklahoma",[4],416,false,110,17,46423,56,281,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Smoking Cessation",20,{"name":18,"count":19},"Atrial Fibrillation",10,{"name":21,"count":22},"Obesity",9,{"name":24,"count":25},"Healthy",8,{"name":27,"count":25},"Endometrial Cancer",{"name":29,"count":30},"Cigarette Smoking",7,{"name":32,"count":30},"Peripheral Artery Disease",{"name":34,"count":35},"Prostate Cancer",6,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03587038","OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma","2020-12-23","OKN 007",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04004442","Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma","2022-04-07","Avelumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03771651","Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube","2022-05-06","Aspirin 81 mg",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05176379","Endothelial Derived Hyperpolarization Factor and Vascular Control","2024-12","Fluconazole 150 mg",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05934669","IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED","2025-05","Intranasal Midazolam",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06137040","Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation","2025-05-31","Magnesium Sulfate within the first hour",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06129604","Pilot Window of Opportunity Trial (POET)","2025-08-22","TPST-1495",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT03932409","Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer","2025-09-25","Pembrolizumab",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04373642","\"QUAD SHOT\" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer","2025-10-14","Pebrolizumab + QUADSHOT Radiotherapy",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04887558","Mobile App for Smoking Cessation and Mental Health","2026-01-06","Smart-T Mental Health and NRT",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,161,197,217,235,261,279,297,323,349,378,396,414,439,486,520,596,639,675,711,729,749,776,794,812,835,863,881,906,928,955,973,991,1009,1027,1049,1091,1124,1147,1175,1193,1219,1242,1260,1285,1310,1328,1351,1402,1423,1446,1467,1492,1515,1533,1557,1586,1624,1657,1681,1706,1724,1750,1768,1792,1819,1842,1865,1898,1916,1939,1964,1982,2009,2027,2052,2070,2094,2121,2139,2165,2183,2215,2241,2263,2290,2308,2331,2349,2367,2385,2403,2421,2439,2457,2482,2505,2530,2552,2570,2594,2618,2656,2679,2703,2727,2753,2771,2795,2819,2837,2862,2888,2906,2930,2956,2974,2997,3022,3047,3076,3094,3119,3143,3168,3186,3204,3229,3267,3302,3328,3351,3377,3395,3419,3443,3469,3487,3505,3531,3555,3578,3596,3614,3637,3655,3678,3703,3721,3744,3762,3786,3811,3829,3853,3879,3897,3915,3937,3955,3981,4006,4024,4042,4065],{"intervention":96,"totalTrials":97,"cells":98},"Nicotine patch",5,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":127,"PHASE4":129,"NA":153},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":126,"soonestReadout":121},[106,116],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT05253573","Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos","COMPLETED",[90],"2023-08-31","2022-04-20",80,[29],[96],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":125},"NCT05233228","Mobile Health Technology for Personalized Tobacco Cessation Support in Laos","RECRUITING",[90],"2026-08-31","2022-04-27",500,[29],[96],1,{"trials":128,"activeCount":101},[],{"trials":130,"activeCount":126,"soonestReadout":145},[131,141],{"nctId":132,"briefTitle":133,"status":109,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":16,"conditions":138,"interventions":139},"NCT03060278","Smartphone-delivered Automated Video-assisted Smoking Treatment for Patrons of a Food Resource Center",[92],"2017-05-19","2017-12-31","2017-05-15",[15],[140],"nicotine patch",{"nctId":142,"briefTitle":143,"status":119,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":113,"conditions":147,"interventions":150},"NCT05587361","Beta-Adrenergic Modulation of Drug Cue Reactivity",[92],"2027-03-31","2024-11-26",[148,149,29],"Tobacco Use Disorder","Nicotine Dependence",[151,152],"Propranolol","Nicotine Patch",{"trials":154,"activeCount":101},[155],{"nctId":156,"briefTitle":157,"status":109,"phases":158,"primaryCompletion":135,"completion":136,"start":137,"enrollment":16,"conditions":159,"interventions":160},"NCT03082482","Smartphone-delivered Automated Video-assisted Smoking Treatment for People Living With HIV",[93],[15],[140],{"intervention":162,"totalTrials":163,"cells":164},"Nicotinamide riboside",2,{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":180,"PHASE4":182,"NA":195},{"trials":166,"activeCount":101},[],{"trials":168,"activeCount":101},[],{"trials":170,"activeCount":101},[171],{"nctId":172,"briefTitle":173,"status":109,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":25,"conditions":178,"interventions":179},"NCT06534944","NAD Supplementation and Vascular Health in PAD",[89,90],"2024-07-30","2024-12-30","2023-02-27",[32],[162],{"trials":181,"activeCount":101},[],{"trials":183,"activeCount":126,"soonestReadout":188},[184],{"nctId":185,"briefTitle":186,"status":119,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT05483465","The Effect of NAD Supplementation on Brain Vascular Health in Aging",[92],"2027-06","2027-12","2023-05-03",214,[193],"Aging",[162],{"trials":196,"activeCount":101},[],{"intervention":56,"totalTrials":126,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":215},{"trials":200,"activeCount":101},[],{"trials":202,"activeCount":101},[],{"trials":204,"activeCount":101},[],{"trials":206,"activeCount":101},[],{"trials":208,"activeCount":126,"soonestReadout":55},[209],{"nctId":53,"briefTitle":54,"status":119,"phases":210,"primaryCompletion":55,"completion":60,"start":211,"enrollment":212,"conditions":213,"interventions":214},[92],"2022-02-19",30,[24],[56],{"trials":216,"activeCount":101},[],{"intervention":151,"totalTrials":126,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":233},{"trials":220,"activeCount":101},[],{"trials":222,"activeCount":101},[],{"trials":224,"activeCount":101},[],{"trials":226,"activeCount":101},[],{"trials":228,"activeCount":126,"soonestReadout":145},[229],{"nctId":142,"briefTitle":143,"status":119,"phases":230,"primaryCompletion":145,"completion":145,"start":146,"enrollment":113,"conditions":231,"interventions":232},[92],[148,149,29],[151,152],{"trials":234,"activeCount":101},[],{"intervention":61,"totalTrials":126,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":259},{"trials":238,"activeCount":101},[],{"trials":240,"activeCount":101},[],{"trials":242,"activeCount":101},[],{"trials":244,"activeCount":101},[],{"trials":246,"activeCount":126,"soonestReadout":60},[247],{"nctId":58,"briefTitle":59,"status":119,"phases":248,"primaryCompletion":60,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":256},[92],"2025-06","2023-11-14",90,[253,254,255],"Laceration of Skin","Anxiety","Discharge Time",[61,257,258],"Intranasal Dexmedetomidine","Intranasal Ketamine",{"trials":260,"activeCount":101},[],{"intervention":257,"totalTrials":126,"cells":262},{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":277},{"trials":264,"activeCount":101},[],{"trials":266,"activeCount":101},[],{"trials":268,"activeCount":101},[],{"trials":270,"activeCount":101},[],{"trials":272,"activeCount":126,"soonestReadout":60},[273],{"nctId":58,"briefTitle":59,"status":119,"phases":274,"primaryCompletion":60,"completion":249,"start":250,"enrollment":251,"conditions":275,"interventions":276},[92],[253,254,255],[61,257,258],{"trials":278,"activeCount":101},[],{"intervention":258,"totalTrials":126,"cells":280},{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":295},{"trials":282,"activeCount":101},[],{"trials":284,"activeCount":101},[],{"trials":286,"activeCount":101},[],{"trials":288,"activeCount":101},[],{"trials":290,"activeCount":126,"soonestReadout":60},[291],{"nctId":58,"briefTitle":59,"status":119,"phases":292,"primaryCompletion":60,"completion":249,"start":250,"enrollment":251,"conditions":293,"interventions":294},[92],[253,254,255],[61,257,258],{"trials":296,"activeCount":101},[],{"intervention":298,"totalTrials":126,"cells":299},"Ketamine",{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":321},{"trials":301,"activeCount":101},[],{"trials":303,"activeCount":101},[],{"trials":305,"activeCount":101},[],{"trials":307,"activeCount":101},[],{"trials":309,"activeCount":126,"soonestReadout":314},[310],{"nctId":311,"briefTitle":312,"status":119,"phases":313,"primaryCompletion":314,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":320},"NCT04248205","Ketamine for Post-operative Analgesia in Hemorrhoidectomy",[92],"2027-01","2027-07","2020-06-15",100,[319],"Hemorrhoids",[298],{"trials":322,"activeCount":101},[],{"intervention":324,"totalTrials":126,"cells":325},"Semaglutide",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":347},{"trials":327,"activeCount":101},[],{"trials":329,"activeCount":101},[],{"trials":331,"activeCount":101},[],{"trials":333,"activeCount":101},[],{"trials":335,"activeCount":126,"soonestReadout":340},[336],{"nctId":337,"briefTitle":338,"status":119,"phases":339,"primaryCompletion":340,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":346},"NCT06986993","Impact of Semaglutide on Tobacco Use and Related Health Behaviors",[92],"2028-05-30","2028-06-30","2024-07-01",40,[345],"Tobacco Use",[324],{"trials":348,"activeCount":101},[],{"intervention":350,"totalTrials":126,"cells":351},"Meloxicam 7.5 mg",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":376},{"trials":353,"activeCount":101},[],{"trials":355,"activeCount":101},[],{"trials":357,"activeCount":101},[],{"trials":359,"activeCount":101},[],{"trials":361,"activeCount":126,"soonestReadout":366},[362],{"nctId":363,"briefTitle":364,"status":119,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":373},"NCT07200544","Meloxicam in Mohs Micrographic Surgery",[92],"2026-06-02","2026-08-02","2025-10-15",300,[371,372],"Postoperative Pain, Acute","Skin Cancer",[350,374,375],"Meloxicam 15 mg","Acetaminophen 500mg",{"trials":377,"activeCount":101},[],{"intervention":374,"totalTrials":126,"cells":379},{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":386,"PHASE4":388,"NA":394},{"trials":381,"activeCount":101},[],{"trials":383,"activeCount":101},[],{"trials":385,"activeCount":101},[],{"trials":387,"activeCount":101},[],{"trials":389,"activeCount":126,"soonestReadout":366},[390],{"nctId":363,"briefTitle":364,"status":119,"phases":391,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":392,"interventions":393},[92],[371,372],[350,374,375],{"trials":395,"activeCount":101},[],{"intervention":375,"totalTrials":126,"cells":397},{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":412},{"trials":399,"activeCount":101},[],{"trials":401,"activeCount":101},[],{"trials":403,"activeCount":101},[],{"trials":405,"activeCount":101},[],{"trials":407,"activeCount":126,"soonestReadout":366},[408],{"nctId":363,"briefTitle":364,"status":119,"phases":409,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":410,"interventions":411},[92],[371,372],[350,374,375],{"trials":413,"activeCount":101},[],{"intervention":415,"totalTrials":126,"cells":416},"Dapagliflozin 10Mg Tab",{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":435,"NA":437},{"trials":418,"activeCount":101},[],{"trials":420,"activeCount":101},[],{"trials":422,"activeCount":101},[],{"trials":424,"activeCount":126,"soonestReadout":429},[425],{"nctId":426,"briefTitle":427,"status":119,"phases":428,"primaryCompletion":429,"completion":189,"start":430,"enrollment":431,"conditions":432,"interventions":434},"NCT05174052","Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)",[91],"2027-04","2022-06-01",28,[433,18],"Diabetes Mellitus",[415],{"trials":436,"activeCount":101},[],{"trials":438,"activeCount":101},[],{"intervention":76,"totalTrials":440,"cells":441},3,{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":456,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":443,"activeCount":101},[],{"trials":445,"activeCount":126,"soonestReadout":75},[446],{"nctId":73,"briefTitle":74,"status":447,"phases":448,"primaryCompletion":75,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},"ACTIVE_NOT_RECRUITING",[89],"2027-06-25","2020-02-19",45,[27],[76,454,455],"Paclitaxel","Carboplatin",{"trials":457,"activeCount":126,"soonestReadout":473},[458,469],{"nctId":459,"briefTitle":460,"status":461,"phases":462,"primaryCompletion":463,"completion":188,"start":464,"enrollment":101,"conditions":465,"interventions":467},"NCT05263609","Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib","WITHDRAWN",[90],"2026-06","2022-06",[466],"Renal Cell Cancer",[468,76],"Axitinib",{"nctId":470,"briefTitle":471,"status":119,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":212,"conditions":476,"interventions":478},"NCT07183319","Circulating Tumor DNA Response In Urothelial Cancer",[90],"2028-03","2029-03","2026-01-19",[477],"Urothelial Carcinoma",[479,76,479],"Pembrolizumab & Enfortumab Vedotin",{"trials":481,"activeCount":101},[],{"trials":483,"activeCount":101},[],{"trials":485,"activeCount":101},[],{"intervention":487,"totalTrials":163,"cells":488},"QuitGuide + NRT",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":504,"PHASE4":516,"NA":518},{"trials":490,"activeCount":101},[],{"trials":492,"activeCount":101},[],{"trials":494,"activeCount":126,"soonestReadout":85},[495],{"nctId":83,"briefTitle":84,"status":447,"phases":496,"primaryCompletion":85,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":502},[90],"2028-12","2021-12-14",64,[15,501],"Mental Illness",[86,503,487],"Smart-T Mental Health+ and NRT",{"trials":505,"activeCount":101},[506],{"nctId":507,"briefTitle":508,"status":109,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":514},"NCT03740490","Smartphone Based Smoking Cessation Intervention",[90,91],"2023-11-17","2019-08-26",454,[15],[515,487],"Smart-T + NRT",{"trials":517,"activeCount":101},[],{"trials":519,"activeCount":101},[],{"intervention":521,"totalTrials":97,"cells":522},"Bevacizumab",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":524,"activeCount":101},[],{"trials":526,"activeCount":101},[],{"trials":528,"activeCount":126,"soonestReadout":584},[529,542,554,567,580],{"nctId":530,"briefTitle":531,"status":532,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":30,"conditions":536,"interventions":540},"NCT05523440","Bevacizumab and\u002For Niraparib in Patients With Recurrent Endometrial and\u002For Ovarian Cancer With ARID1A Mutation","TERMINATED",[90],"2025-01-08","2023-02-15",[537,538,539],"Recurrent Endometrial Carcinoma","Recurrent Ovarian Carcinoma","ARID1A Gene Mutation",[521,541],"Niraparib",{"nctId":543,"briefTitle":544,"status":109,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT03476798","Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium",[90],"2020-05-12","2023-09-29","2018-06-29",49,[551,27],"Cervical Cancer",[553,521],"Rucaparib",{"nctId":555,"briefTitle":556,"status":109,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":563},"NCT00222469","Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer",[90],"2007-05","2005-08",50,[562],"Metastatic Pancreatic Cancer",[564,565,566],"bevacizumab","gemcitabine","oxaliplatin",{"nctId":568,"briefTitle":569,"status":461,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":101,"conditions":574,"interventions":578},"NCT03836157","Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer",[90],"2021-11-30","2022-05","2019-05-31",[27,575,576,577],"Endometrial Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Clear Cell Adenocarcinoma",[579,521],"Mirvetuximab Soravtansine",{"nctId":581,"briefTitle":582,"status":447,"phases":583,"primaryCompletion":584,"completion":585,"start":586,"enrollment":8,"conditions":587,"interventions":588},"NCT03526432","Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer",[90],"2026-03-31","2026-09","2018-08-08",[27],[521,589],"Atezolizumab",{"trials":591,"activeCount":101},[],{"trials":593,"activeCount":101},[],{"trials":595,"activeCount":101},[],{"intervention":541,"totalTrials":440,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":599,"activeCount":101},[],{"trials":601,"activeCount":101},[],{"trials":603,"activeCount":126,"soonestReadout":625},[604,617,621],{"nctId":605,"briefTitle":606,"status":532,"phases":607,"primaryCompletion":250,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":616},"NCT05297864","PARP Inhibition for Gliomas (PI-4G or π4g)",[90],"2024-02-06","2022-06-09",15,[612,613,614,615],"Recurrent Glioblastoma","Recurrent Astrocytoma","Recurrent Oligodendroglioma","Recurrent Glioma",[541],{"nctId":530,"briefTitle":531,"status":532,"phases":618,"primaryCompletion":534,"completion":534,"start":535,"enrollment":30,"conditions":619,"interventions":620},[90],[537,538,539],[521,541],{"nctId":622,"briefTitle":623,"status":447,"phases":624,"primaryCompletion":625,"completion":315,"start":626,"enrollment":627,"conditions":628,"interventions":631},"NCT04068753","Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer",[90],"2026-12","2020-02-26",66,[629,630],"Recurrent Cervix Cancer","Progressive Cervix Cancer",[541,632],"dostarlimab",{"trials":634,"activeCount":101},[],{"trials":636,"activeCount":101},[],{"trials":638,"activeCount":101},[],{"intervention":640,"totalTrials":163,"cells":641},"Varenicline",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":643,"activeCount":101},[],{"trials":645,"activeCount":101},[],{"trials":647,"activeCount":126,"soonestReadout":653},[648,659],{"nctId":649,"briefTitle":650,"status":651,"phases":652,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":657},"NCT07099638","Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation","NOT_YET_RECRUITING",[90],"2029-06-01","2026-05",496,[15],[640,658],"Nicotine lozenge",{"nctId":660,"briefTitle":661,"status":532,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":667},"NCT03722966","Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)",[90],"2022-02-07","2020-01-07",34,[15],[640,668],"Oral Nicotine Replacement Therapy",{"trials":670,"activeCount":101},[],{"trials":672,"activeCount":101},[],{"trials":674,"activeCount":101},[],{"intervention":676,"totalTrials":163,"cells":677},"Azithromycin",{"EARLY_PHASE1":678,"PHASE1":691,"PHASE2":693,"PHASE3":705,"PHASE4":707,"NA":709},{"trials":679,"activeCount":101},[680],{"nctId":681,"briefTitle":682,"status":109,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT03801252","Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term",[88],"2021-06-01","2018-12-12",186,[21,688],"Induction of Labor Affected Fetus \u002F Newborn",[690,676],"Cefazolin",{"trials":692,"activeCount":101},[],{"trials":694,"activeCount":126,"soonestReadout":497},[695],{"nctId":696,"briefTitle":697,"status":119,"phases":698,"primaryCompletion":497,"completion":497,"start":699,"enrollment":700,"conditions":701,"interventions":704},"NCT06488781","Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0",[90],"2025-04-29",787,[702,703],"Obesity in Pregnancy","Labor Complication",[676],{"trials":706,"activeCount":101},[],{"trials":708,"activeCount":101},[],{"trials":710,"activeCount":101},[],{"intervention":658,"totalTrials":126,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":714,"activeCount":101},[],{"trials":716,"activeCount":101},[],{"trials":718,"activeCount":126,"soonestReadout":653},[719],{"nctId":649,"briefTitle":650,"status":651,"phases":720,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":721,"interventions":722},[90],[15],[640,658],{"trials":724,"activeCount":101},[],{"trials":726,"activeCount":101},[],{"trials":728,"activeCount":101},[],{"intervention":81,"totalTrials":126,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":732,"activeCount":101},[],{"trials":734,"activeCount":101},[],{"trials":736,"activeCount":126,"soonestReadout":80},[737],{"nctId":78,"briefTitle":79,"status":447,"phases":738,"primaryCompletion":80,"completion":739,"start":40,"enrollment":212,"conditions":740,"interventions":742},[90],"2026-10",[741],"Head and Neck Cancer",[81],{"trials":744,"activeCount":101},[],{"trials":746,"activeCount":101},[],{"trials":748,"activeCount":101},[],{"intervention":750,"totalTrials":126,"cells":751},"nab-Sirolimus",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":753,"activeCount":101},[],{"trials":755,"activeCount":101},[],{"trials":757,"activeCount":126,"soonestReadout":762},[758],{"nctId":759,"briefTitle":760,"status":119,"phases":761,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT06494150","Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)",[90],"2027-08","2029-09","2024-12-26",37,[767],"Low Grade Ovarian Serous Adenocarcinoma",[750,769],"Fulvestrant",{"trials":771,"activeCount":101},[],{"trials":773,"activeCount":101},[],{"trials":775,"activeCount":101},[],{"intervention":769,"totalTrials":126,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":779,"activeCount":101},[],{"trials":781,"activeCount":101},[],{"trials":783,"activeCount":126,"soonestReadout":762},[784],{"nctId":759,"briefTitle":760,"status":119,"phases":785,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":786,"interventions":787},[90],[767],[750,769],{"trials":789,"activeCount":101},[],{"trials":791,"activeCount":101},[],{"trials":793,"activeCount":101},[],{"intervention":479,"totalTrials":126,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":797,"activeCount":101},[],{"trials":799,"activeCount":101},[],{"trials":801,"activeCount":126,"soonestReadout":473},[802],{"nctId":470,"briefTitle":471,"status":119,"phases":803,"primaryCompletion":473,"completion":474,"start":475,"enrollment":212,"conditions":804,"interventions":805},[90],[477],[479,76,479],{"trials":807,"activeCount":101},[],{"trials":809,"activeCount":101},[],{"trials":811,"activeCount":101},[],{"intervention":813,"totalTrials":126,"cells":814},"Ketamine Topical",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":816,"activeCount":101},[],{"trials":818,"activeCount":101},[],{"trials":820,"activeCount":126,"soonestReadout":188},[821],{"nctId":822,"briefTitle":823,"status":651,"phases":824,"primaryCompletion":188,"completion":825,"start":463,"enrollment":826,"conditions":827,"interventions":828},"NCT06660017","Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse",[90],"2027-11",62,[741],[813],{"trials":830,"activeCount":101},[],{"trials":832,"activeCount":101},[],{"trials":834,"activeCount":101},[],{"intervention":836,"totalTrials":126,"cells":837},"Avutometinib (VS-6766) + defactinib",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":857,"PHASE4":859,"NA":861},{"trials":839,"activeCount":101},[],{"trials":841,"activeCount":101},[],{"trials":843,"activeCount":126,"soonestReadout":189},[844],{"nctId":845,"briefTitle":846,"status":119,"phases":847,"primaryCompletion":189,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":856},"NCT05512208","A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib",[90],"2029-12","2023-02-06",55,[852,853,854,551,855],"Endometrioid Cancer","Mucinous Ovarian Cancer","High Grade Serous Ovarian Cancer","Solid Tumor",[836],{"trials":858,"activeCount":101},[],{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":101},[],{"intervention":589,"totalTrials":126,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":866,"activeCount":101},[],{"trials":868,"activeCount":101},[],{"trials":870,"activeCount":126,"soonestReadout":584},[871],{"nctId":581,"briefTitle":582,"status":447,"phases":872,"primaryCompletion":584,"completion":585,"start":586,"enrollment":8,"conditions":873,"interventions":874},[90],[27],[521,589],{"trials":876,"activeCount":101},[],{"trials":878,"activeCount":101},[],{"trials":880,"activeCount":101},[],{"intervention":882,"totalTrials":126,"cells":883},"Disulfiram",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":885,"activeCount":101},[],{"trials":887,"activeCount":101},[],{"trials":889,"activeCount":126,"soonestReadout":894},[890],{"nctId":891,"briefTitle":892,"status":651,"phases":893,"primaryCompletion":894,"completion":895,"start":654,"enrollment":16,"conditions":896,"interventions":899},"NCT07534332","Disulfiram in Rheumatoid Arthritis",[90],"2027-04-30","2028-04-30",[897,898,21],"Rheumatoid Arthritis","Inflammation",[882],{"trials":901,"activeCount":101},[],{"trials":903,"activeCount":101},[],{"trials":905,"activeCount":101},[],{"intervention":71,"totalTrials":126,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":909,"activeCount":101},[],{"trials":911,"activeCount":101},[],{"trials":913,"activeCount":126,"soonestReadout":70},[914],{"nctId":68,"briefTitle":69,"status":447,"phases":915,"primaryCompletion":70,"completion":916,"start":917,"enrollment":19,"conditions":918,"interventions":921},[90],"2026-06-30","2024-04-03",[919,920],"Colorectal Carcinoma (CRC)","Endometrial Carcinoma (EC)",[71],{"trials":923,"activeCount":101},[],{"trials":925,"activeCount":101},[],{"trials":927,"activeCount":101},[],{"intervention":929,"totalTrials":126,"cells":930},"Cemiplimab 350 MG Intravenous Solution",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":949,"PHASE4":951,"NA":953},{"trials":932,"activeCount":101},[],{"trials":934,"activeCount":101},[],{"trials":936,"activeCount":126,"soonestReadout":941},[937],{"nctId":938,"briefTitle":939,"status":119,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":947},"NCT07223541","Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma",[90],"2029-08","2031-08","2026-01-15",72,[946],"Clear Cell Renal Cell Carcinoma",[929,948],"Fianlimab 1600 MG Intravenous Solution",{"trials":950,"activeCount":101},[],{"trials":952,"activeCount":101},[],{"trials":954,"activeCount":101},[],{"intervention":948,"totalTrials":126,"cells":956},{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":958,"activeCount":101},[],{"trials":960,"activeCount":101},[],{"trials":962,"activeCount":126,"soonestReadout":941},[963],{"nctId":938,"briefTitle":939,"status":119,"phases":964,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":965,"interventions":966},[90],[946],[929,948],{"trials":968,"activeCount":101},[],{"trials":970,"activeCount":101},[],{"trials":972,"activeCount":101},[],{"intervention":632,"totalTrials":126,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":976,"activeCount":101},[],{"trials":978,"activeCount":101},[],{"trials":980,"activeCount":126,"soonestReadout":625},[981],{"nctId":622,"briefTitle":623,"status":447,"phases":982,"primaryCompletion":625,"completion":315,"start":626,"enrollment":627,"conditions":983,"interventions":984},[90],[629,630],[541,632],{"trials":986,"activeCount":101},[],{"trials":988,"activeCount":101},[],{"trials":990,"activeCount":101},[],{"intervention":86,"totalTrials":126,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":994,"activeCount":101},[],{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":126,"soonestReadout":85},[999],{"nctId":83,"briefTitle":84,"status":447,"phases":1000,"primaryCompletion":85,"completion":497,"start":498,"enrollment":499,"conditions":1001,"interventions":1002},[90],[15,501],[86,503,487],{"trials":1004,"activeCount":101},[],{"trials":1006,"activeCount":101},[],{"trials":1008,"activeCount":101},[],{"intervention":503,"totalTrials":126,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1012,"activeCount":101},[],{"trials":1014,"activeCount":101},[],{"trials":1016,"activeCount":126,"soonestReadout":85},[1017],{"nctId":83,"briefTitle":84,"status":447,"phases":1018,"primaryCompletion":85,"completion":497,"start":498,"enrollment":499,"conditions":1019,"interventions":1020},[90],[15,501],[86,503,487],{"trials":1022,"activeCount":101},[],{"trials":1024,"activeCount":101},[],{"trials":1026,"activeCount":101},[],{"intervention":1028,"totalTrials":126,"cells":1029},"Echothiophate Iodide 0.125% Ophthalmic Solution",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1031,"activeCount":101},[],{"trials":1033,"activeCount":101},[],{"trials":1035,"activeCount":126,"soonestReadout":625},[1036],{"nctId":1037,"briefTitle":1038,"status":651,"phases":1039,"primaryCompletion":625,"completion":625,"start":463,"enrollment":16,"conditions":1040,"interventions":1042},"NCT07554131","Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia",[90],[1041],"Refractory Amblyopia",[1028],{"trials":1044,"activeCount":101},[],{"trials":1046,"activeCount":101},[],{"trials":1048,"activeCount":101},[],{"intervention":455,"totalTrials":440,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1071,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1052,"activeCount":101},[],{"trials":1054,"activeCount":126,"soonestReadout":75},[1055,1059],{"nctId":73,"briefTitle":74,"status":447,"phases":1056,"primaryCompletion":75,"completion":449,"start":450,"enrollment":451,"conditions":1057,"interventions":1058},[89],[27],[76,454,455],{"nctId":1060,"briefTitle":1061,"status":109,"phases":1062,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1069},"NCT03206177","Paclitaxel\u002FCarboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary",[89],"2021-07-28","2024-02-13","2017-08-23",26,[1068],"Carcinosarcoma, Ovarian",[1070,454,455],"Galunisertib",{"trials":1072,"activeCount":101},[1073],{"nctId":1074,"briefTitle":1075,"status":109,"phases":1076,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1084},"NCT03189446","Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer",[90],"2019-12-13","2021-10-06","2017-10-02",39,[27,1082,1083],"Papillary Serous","Clear Cell Endometrial Cancer",[455,454],{"trials":1086,"activeCount":101},[],{"trials":1088,"activeCount":101},[],{"trials":1090,"activeCount":101},[],{"intervention":46,"totalTrials":163,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1104,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1094,"activeCount":101},[],{"trials":1096,"activeCount":126,"soonestReadout":45},[1097],{"nctId":43,"briefTitle":44,"status":447,"phases":1098,"primaryCompletion":45,"completion":739,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1102},[89],"2020-02-17",19,[477],[46,1103],"AVB-S6-500",{"trials":1105,"activeCount":101},[1106],{"nctId":1107,"briefTitle":1108,"status":109,"phases":1109,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1113,"conditions":1114,"interventions":1116},"NCT03892642","Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer",[89,90],"2021-03-23","2023-08-13","2019-05-01",18,[1115],"Bladder Cancer",[46,1117],"BCG",{"trials":1119,"activeCount":101},[],{"trials":1121,"activeCount":101},[],{"trials":1123,"activeCount":101},[],{"intervention":1125,"totalTrials":126,"cells":1126},"OK-1",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1139,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1128,"activeCount":101},[],{"trials":1130,"activeCount":126,"soonestReadout":654},[1131],{"nctId":1132,"briefTitle":1133,"status":119,"phases":1134,"primaryCompletion":654,"completion":188,"start":1135,"enrollment":560,"conditions":1136,"interventions":1138},"NCT04928508","Advanced or Recurrent Solid Tumors Treated With SHetA2",[89],"2022-07-27",[1137],"Solid Tumor, Adult",[1125],{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":101},[],{"trials":1146,"activeCount":101},[],{"intervention":1148,"totalTrials":126,"cells":1149},"FLT",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1151,"activeCount":101},[],{"trials":1153,"activeCount":126,"soonestReadout":429},[1154],{"nctId":1155,"briefTitle":1156,"status":119,"phases":1157,"primaryCompletion":429,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1166},"NCT03633955","Pilot Imaging Study of Leukemia",[89],"2029-04","2023-01-19",60,[1162,1163,1164,1165],"Acute Lymphocytic Leukemia","Acute Myeloid Leukemia","Ambiguous Lineage Leukemia or Lymphoma","Myeloma",[1148],{"trials":1168,"activeCount":101},[],{"trials":1170,"activeCount":101},[],{"trials":1172,"activeCount":101},[],{"trials":1174,"activeCount":101},[],{"intervention":1103,"totalTrials":126,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":101},[],{"trials":1180,"activeCount":126,"soonestReadout":45},[1181],{"nctId":43,"briefTitle":44,"status":447,"phases":1182,"primaryCompletion":45,"completion":739,"start":1099,"enrollment":1100,"conditions":1183,"interventions":1184},[89],[477],[46,1103],{"trials":1186,"activeCount":101},[],{"trials":1188,"activeCount":101},[],{"trials":1190,"activeCount":101},[],{"trials":1192,"activeCount":101},[],{"intervention":1194,"totalTrials":126,"cells":1195},"Relugolix and Enzalutamide",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1197,"activeCount":101},[],{"trials":1199,"activeCount":126,"soonestReadout":1204},[1200],{"nctId":1201,"briefTitle":1202,"status":119,"phases":1203,"primaryCompletion":1204,"completion":1205,"start":764,"enrollment":1206,"conditions":1207,"interventions":1210},"NCT06130995","Relugolix + Enzalutamide Study in High-Risk Prostate Cancer",[89],"2029-01","2030-01",46,[1208,1209],"Androgen Deprivation Therapy","Locally Advanced Prostate Cancer",[1194],{"trials":1212,"activeCount":101},[],{"trials":1214,"activeCount":101},[],{"trials":1216,"activeCount":101},[],{"trials":1218,"activeCount":101},[],{"intervention":41,"totalTrials":126,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1234,"PHASE3":1236,"PHASE4":1238,"NA":1240},{"trials":1222,"activeCount":101},[],{"trials":1224,"activeCount":126,"soonestReadout":40},[1225],{"nctId":38,"briefTitle":39,"status":447,"phases":1226,"primaryCompletion":40,"completion":1227,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1232},[89],"2026-11","2018-09-03",27,[1231],"Glioblastoma",[41,1233],"Temozolomide",{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[],{"trials":1239,"activeCount":101},[],{"trials":1241,"activeCount":101},[],{"intervention":1233,"totalTrials":126,"cells":1243},{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1252,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1245,"activeCount":101},[],{"trials":1247,"activeCount":126,"soonestReadout":40},[1248],{"nctId":38,"briefTitle":39,"status":447,"phases":1249,"primaryCompletion":40,"completion":1227,"start":1228,"enrollment":1229,"conditions":1250,"interventions":1251},[89],[1231],[41,1233],{"trials":1253,"activeCount":101},[],{"trials":1255,"activeCount":101},[],{"trials":1257,"activeCount":101},[],{"trials":1259,"activeCount":101},[],{"intervention":1261,"totalTrials":126,"cells":1262},"Sipuleucel-T",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1264,"activeCount":101},[],{"trials":1266,"activeCount":126,"soonestReadout":1271},[1267],{"nctId":1268,"briefTitle":1269,"status":447,"phases":1270,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":610,"conditions":1274,"interventions":1276},"NCT05806814","Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer",[89],"2026-05-13","2028-05-13","2023-11-12",[1275],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[1261],{"trials":1278,"activeCount":101},[],{"trials":1280,"activeCount":101},[],{"trials":1282,"activeCount":101},[],{"trials":1284,"activeCount":101},[],{"intervention":1286,"totalTrials":126,"cells":1287},"Vantage Hemp CBD Isolate + Silicone patch",{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1289,"activeCount":101},[],{"trials":1291,"activeCount":126,"soonestReadout":315},[1292],{"nctId":1293,"briefTitle":1294,"status":651,"phases":1295,"primaryCompletion":315,"completion":1296,"start":654,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT06129591","Topical CBD Scar Healing Study",[89],"2028-07",22,[1299],"Paramedian Forehead Flap",[1286,1301],"Silicone patch",{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":101},[],{"trials":1307,"activeCount":101},[],{"trials":1309,"activeCount":101},[],{"intervention":1301,"totalTrials":126,"cells":1311},{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1313,"activeCount":101},[],{"trials":1315,"activeCount":126,"soonestReadout":315},[1316],{"nctId":1293,"briefTitle":1294,"status":651,"phases":1317,"primaryCompletion":315,"completion":1296,"start":654,"enrollment":1297,"conditions":1318,"interventions":1319},[89],[1299],[1286,1301],{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":101},[],{"trials":1325,"activeCount":101},[],{"trials":1327,"activeCount":101},[],{"intervention":1329,"totalTrials":126,"cells":1330},"FLT imaging and TK1 blood measurements",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1343,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":126,"soonestReadout":1227},[1335],{"nctId":1336,"briefTitle":1337,"status":119,"phases":1338,"primaryCompletion":1227,"completion":825,"start":1339,"enrollment":11,"conditions":1340,"interventions":1342},"NCT03541889","REVEAL Biomarkers of Engraftment After Alternative Donor HSCT",[89],"2021-02-05",[1341],"Primary Graft Failure",[1329],{"trials":1344,"activeCount":101},[],{"trials":1346,"activeCount":101},[],{"trials":1348,"activeCount":101},[],{"trials":1350,"activeCount":101},[],{"intervention":454,"totalTrials":97,"cells":1352},{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1365,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1354,"activeCount":101},[],{"trials":1356,"activeCount":126,"soonestReadout":75},[1357,1361],{"nctId":73,"briefTitle":74,"status":447,"phases":1358,"primaryCompletion":75,"completion":449,"start":450,"enrollment":451,"conditions":1359,"interventions":1360},[89],[27],[76,454,455],{"nctId":1060,"briefTitle":1061,"status":109,"phases":1362,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":1066,"conditions":1363,"interventions":1364},[89],[1068],[1070,454,455],{"trials":1366,"activeCount":101},[1367,1371],{"nctId":1074,"briefTitle":1075,"status":109,"phases":1368,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1369,"interventions":1370},[90],[27,1082,1083],[455,454],{"nctId":1372,"briefTitle":1373,"status":109,"phases":1374,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":16,"conditions":1377,"interventions":1381},"NCT00511992","Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer",[90],"2015-08-03","2007-07",[1378,1379,1380],"Advanced Ovarian Carcinoma","Primary Peritoneal Carcinoma","Ovarian Carcinosarcoma",[1382,454,1383],"Avastin","Cisplatin",{"trials":1385,"activeCount":101},[],{"trials":1387,"activeCount":101},[],{"trials":1389,"activeCount":101},[1390],{"nctId":1391,"briefTitle":1392,"status":109,"phases":1393,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":1229,"conditions":1397,"interventions":1401},"NCT00821028","Local Paclitaxel Delivery for SFA Disease",[93],"2011-12","2012-04","2009-01",[1398,1399,1400],"Atherosclerosis","Angioplasty","Peripheral Arterial Disease",[454],{"intervention":51,"totalTrials":126,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1405,"activeCount":126,"soonestReadout":50},[1406],{"nctId":48,"briefTitle":49,"status":447,"phases":1407,"primaryCompletion":50,"completion":625,"start":1408,"enrollment":1113,"conditions":1409,"interventions":1412},[88],"2019-03-01",[1410,1411],"Fallopian Tube Cancer","Fallopian Tube Infection",[51],{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[],{"trials":1420,"activeCount":101},[],{"trials":1422,"activeCount":101},[],{"intervention":1424,"totalTrials":126,"cells":1425},"Warmed HSG",{"EARLY_PHASE1":1426,"PHASE1":1436,"PHASE2":1438,"PHASE3":1440,"PHASE4":1442,"NA":1444},{"trials":1427,"activeCount":126,"soonestReadout":625},[1428],{"nctId":1429,"briefTitle":1430,"status":119,"phases":1431,"primaryCompletion":625,"completion":625,"start":654,"enrollment":1432,"conditions":1433,"interventions":1435},"NCT07226310","The Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study",[88],240,[1434],"Infertility",[1424],{"trials":1437,"activeCount":101},[],{"trials":1439,"activeCount":101},[],{"trials":1441,"activeCount":101},[],{"trials":1443,"activeCount":101},[],{"trials":1445,"activeCount":101},[],{"intervention":66,"totalTrials":126,"cells":1447},{"EARLY_PHASE1":1448,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1449,"activeCount":126,"soonestReadout":65},[1450],{"nctId":63,"briefTitle":64,"status":119,"phases":1451,"primaryCompletion":65,"completion":65,"start":1452,"enrollment":317,"conditions":1453,"interventions":1456},[88],"2023-11-30",[1454,1455],"Asthma in Children","Asthma Attack",[66],{"trials":1458,"activeCount":101},[],{"trials":1460,"activeCount":101},[],{"trials":1462,"activeCount":101},[],{"trials":1464,"activeCount":101},[],{"trials":1466,"activeCount":101},[],{"intervention":1468,"totalTrials":126,"cells":1469},"Selpercatinib",{"EARLY_PHASE1":1470,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1471,"activeCount":126,"soonestReadout":1476},[1472],{"nctId":1473,"briefTitle":1474,"status":651,"phases":1475,"primaryCompletion":1476,"completion":1477,"start":1478,"enrollment":30,"conditions":1479,"interventions":1481},"NCT07146893","Feasibility Study for Repurposing RET Inhibitors",[88],"2027-02-23","2028-02-23","2026-02-26",[1480],"Cachexia-Anorexia Syndrome",[1468],{"trials":1483,"activeCount":101},[],{"trials":1485,"activeCount":101},[],{"trials":1487,"activeCount":101},[],{"trials":1489,"activeCount":101},[],{"trials":1491,"activeCount":101},[],{"intervention":1493,"totalTrials":126,"cells":1494},"Group 1 cannabidiol (CBD) with silicone ointment",{"EARLY_PHASE1":1495,"PHASE1":1505,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1513},{"trials":1496,"activeCount":126,"soonestReadout":189},[1497],{"nctId":1498,"briefTitle":1499,"status":651,"phases":1500,"primaryCompletion":189,"completion":189,"start":585,"enrollment":1297,"conditions":1501,"interventions":1503},"NCT05650697","Topical CBD Scar Outcomes Study",[88],[1502],"Forehead; Wound",[1493,1504],"Group 2 silicone patch",{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":101},[],{"trials":1514,"activeCount":101},[],{"intervention":1504,"totalTrials":126,"cells":1516},{"EARLY_PHASE1":1517,"PHASE1":1523,"PHASE2":1525,"PHASE3":1527,"PHASE4":1529,"NA":1531},{"trials":1518,"activeCount":126,"soonestReadout":189},[1519],{"nctId":1498,"briefTitle":1499,"status":651,"phases":1520,"primaryCompletion":189,"completion":189,"start":585,"enrollment":1297,"conditions":1521,"interventions":1522},[88],[1502],[1493,1504],{"trials":1524,"activeCount":101},[],{"trials":1526,"activeCount":101},[],{"trials":1528,"activeCount":101},[],{"trials":1530,"activeCount":101},[],{"trials":1532,"activeCount":101},[],{"intervention":1534,"totalTrials":126,"cells":1535},"Methylene Blue",{"EARLY_PHASE1":1536,"PHASE1":1547,"PHASE2":1549,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1537,"activeCount":126,"soonestReadout":1542},[1538],{"nctId":1539,"briefTitle":1540,"status":651,"phases":1541,"primaryCompletion":1542,"completion":1542,"start":463,"enrollment":560,"conditions":1543,"interventions":1546},"NCT07494773","Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection",[88],"2028-05-31",[1544,1545],"Burns","Wound Infection",[1534],{"trials":1548,"activeCount":101},[],{"trials":1550,"activeCount":101},[],{"trials":1552,"activeCount":101},[],{"trials":1554,"activeCount":101},[],{"trials":1556,"activeCount":101},[],{"intervention":1558,"totalTrials":126,"cells":1559},"Immunotherapy",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1561,"activeCount":101},[],{"trials":1563,"activeCount":101},[],{"trials":1565,"activeCount":101},[],{"trials":1567,"activeCount":101},[],{"trials":1569,"activeCount":101},[],{"trials":1571,"activeCount":126,"soonestReadout":625},[1572],{"nctId":1573,"briefTitle":1574,"status":447,"phases":1575,"primaryCompletion":625,"completion":189,"start":1576,"enrollment":944,"conditions":1577,"interventions":1585},"NCT05863052","Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population",[],"2022-01-31",[1578,1579,1580,1581,1582,1583,1584],"Immune Checkpoint Inhibitors","Metastatic Solid Tumor","Nonsmall Cell Lung Cancer","Melanoma","Renal Cell Carcinoma","Gastrointestinal Cancer","Squamous Cell Carcinoma",[1558],{"intervention":1587,"totalTrials":163,"cells":1588},"Dalteparin sodium",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1622},{"trials":1590,"activeCount":101},[],{"trials":1592,"activeCount":101},[],{"trials":1594,"activeCount":101},[],{"trials":1596,"activeCount":101},[],{"trials":1598,"activeCount":101},[1599,1610],{"nctId":1600,"briefTitle":1601,"status":109,"phases":1602,"primaryCompletion":1603,"completion":1394,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1608},"NCT00245856","Treatment of Upper Extremity Deep-Vein Thrombosis",[92],"2009-03","2002-09",67,[1607],"Deep-Vein Thrombosis",[1587,1609],"Warfarin",{"nctId":1611,"briefTitle":1612,"status":109,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":944,"conditions":1617,"interventions":1621},"NCT00264381","Management of Superficial Thrombophlebitis",[92],"2009-09","2011-09","2002-10",[1618,1619,1620],"Superficial Thrombophlebitis","Upper Extremity Superficial Thrombophlebitis","Lower Extremity Superficial Thrombophlebitis",[1587],{"trials":1623,"activeCount":101},[],{"intervention":1625,"totalTrials":163,"cells":1626},"Dexamethasone",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1655},{"trials":1628,"activeCount":101},[],{"trials":1630,"activeCount":101},[1631],{"nctId":1632,"briefTitle":1633,"status":109,"phases":1634,"primaryCompletion":1394,"completion":1394,"start":1635,"enrollment":610,"conditions":1636,"interventions":1638},"NCT00584168","Using Dexamethasone After Uvulopalatopharyngoplasty",[89],"2005-03",[1637],"Pain",[1625],{"trials":1640,"activeCount":101},[],{"trials":1642,"activeCount":101},[],{"trials":1644,"activeCount":101},[1645],{"nctId":1646,"briefTitle":1647,"status":109,"phases":1648,"primaryCompletion":1649,"completion":1650,"start":1651,"enrollment":8,"conditions":1652,"interventions":1654},"NCT04707534","Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19",[92],"2021-12-31","2022-03-04","2021-01-21",[1653],"Covid19",[1625],{"trials":1656,"activeCount":101},[],{"intervention":1658,"totalTrials":126,"cells":1659},"Sedation with Midazolam, Fentanyl, and Propofol",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1668,"NA":1679},{"trials":1661,"activeCount":101},[],{"trials":1663,"activeCount":101},[],{"trials":1665,"activeCount":101},[],{"trials":1667,"activeCount":101},[],{"trials":1669,"activeCount":101},[1670],{"nctId":1671,"briefTitle":1672,"status":461,"phases":1673,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":101,"conditions":1676,"interventions":1678},"NCT05873465","Cannabis Use on Sedation for Oral Surgery Procedures",[92],"2025-09-30","2023-03-14",[1677],"Cannabis Use",[1658],{"trials":1680,"activeCount":101},[],{"intervention":1682,"totalTrials":126,"cells":1683},"Paxil-CR",{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1688,"PHASE3":1690,"PHASE4":1692,"NA":1704},{"trials":1685,"activeCount":101},[],{"trials":1687,"activeCount":101},[],{"trials":1689,"activeCount":101},[],{"trials":1691,"activeCount":101},[],{"trials":1693,"activeCount":101},[1694],{"nctId":1695,"briefTitle":1696,"status":109,"phases":1697,"primaryCompletion":1698,"completion":1698,"start":1699,"enrollment":1700,"conditions":1701,"interventions":1703},"NCT00229528","Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease",[92],"2006-05","2004-03",25,[1702],"Coronary Artery Disease",[1682],{"trials":1705,"activeCount":101},[],{"intervention":1609,"totalTrials":126,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1714,"PHASE4":1716,"NA":1722},{"trials":1709,"activeCount":101},[],{"trials":1711,"activeCount":101},[],{"trials":1713,"activeCount":101},[],{"trials":1715,"activeCount":101},[],{"trials":1717,"activeCount":101},[1718],{"nctId":1600,"briefTitle":1601,"status":109,"phases":1719,"primaryCompletion":1603,"completion":1394,"start":1604,"enrollment":1605,"conditions":1720,"interventions":1721},[92],[1607],[1587,1609],{"trials":1723,"activeCount":101},[],{"intervention":1725,"totalTrials":126,"cells":1726},"atazanavir",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1748},{"trials":1728,"activeCount":101},[],{"trials":1730,"activeCount":101},[],{"trials":1732,"activeCount":101},[],{"trials":1734,"activeCount":101},[],{"trials":1736,"activeCount":101},[1737],{"nctId":1738,"briefTitle":1739,"status":532,"phases":1740,"primaryCompletion":1741,"completion":1742,"start":1743,"enrollment":1100,"conditions":1744,"interventions":1746},"NCT00420355","Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients",[92],"2007-10","2008-09","2007-04",[1745],"HIV Infection",[1725,1747],"lopinavir\u002Fritonavir",{"trials":1749,"activeCount":101},[],{"intervention":1747,"totalTrials":126,"cells":1751},{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1760,"NA":1766},{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":101},[],{"trials":1757,"activeCount":101},[],{"trials":1759,"activeCount":101},[],{"trials":1761,"activeCount":101},[1762],{"nctId":1738,"briefTitle":1739,"status":532,"phases":1763,"primaryCompletion":1741,"completion":1742,"start":1743,"enrollment":1100,"conditions":1764,"interventions":1765},[92],[1745],[1725,1747],{"trials":1767,"activeCount":101},[],{"intervention":1769,"totalTrials":126,"cells":1770},"MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY",{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1777,"PHASE4":1779,"NA":1790},{"trials":1772,"activeCount":101},[],{"trials":1774,"activeCount":101},[],{"trials":1776,"activeCount":101},[],{"trials":1778,"activeCount":101},[],{"trials":1780,"activeCount":101},[1781],{"nctId":1782,"briefTitle":1783,"status":532,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT00928772","Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety",[92],"2012-02","2009-07",115,[254],[1769],{"trials":1791,"activeCount":101},[],{"intervention":1793,"totalTrials":126,"cells":1794},"Diphenhydramine",{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1803,"NA":1817},{"trials":1796,"activeCount":101},[],{"trials":1798,"activeCount":101},[],{"trials":1800,"activeCount":101},[],{"trials":1802,"activeCount":101},[],{"trials":1804,"activeCount":101},[1805],{"nctId":1806,"briefTitle":1807,"status":109,"phases":1808,"primaryCompletion":1809,"completion":1810,"start":1811,"enrollment":1812,"conditions":1813,"interventions":1816},"NCT01967433","Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids",[92],"2018-03","2018-07","2013-12",120,[1814,1815],"Colonoscopy","Adjunct Anesthesia Medication",[1793],{"trials":1818,"activeCount":101},[],{"intervention":1820,"totalTrials":126,"cells":1821},"Ondansetron",{"EARLY_PHASE1":1822,"PHASE1":1824,"PHASE2":1826,"PHASE3":1828,"PHASE4":1830,"NA":1840},{"trials":1823,"activeCount":101},[],{"trials":1825,"activeCount":101},[],{"trials":1827,"activeCount":101},[],{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":101},[1832],{"nctId":1833,"briefTitle":1834,"status":461,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1836,"enrollment":101,"conditions":1837,"interventions":1839},"NCT01896440","Heart Safety Study of Ondansetron in Children Receiving Chemotherapy",[92],"2013-10",[1838],"Malignant Childhood Neoplasm",[1820],{"trials":1841,"activeCount":101},[],{"intervention":1843,"totalTrials":126,"cells":1844},"Naproxen",{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1851,"PHASE4":1853,"NA":1863},{"trials":1846,"activeCount":101},[],{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":101},[],{"trials":1852,"activeCount":101},[],{"trials":1854,"activeCount":101},[1855],{"nctId":1856,"briefTitle":1857,"status":532,"phases":1858,"completion":1859,"start":1860,"enrollment":343,"conditions":1861,"interventions":1862},"NCT00410995","Effects of Naproxen on Physical Performance",[92],"2006-08","2004-05",[24],[1843],{"trials":1864,"activeCount":101},[],{"intervention":1866,"totalTrials":163,"cells":1867},"Gabapentin",{"EARLY_PHASE1":1868,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1894,"NA":1896},{"trials":1869,"activeCount":101},[1870],{"nctId":1871,"briefTitle":1872,"status":109,"phases":1873,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":343,"conditions":1876,"interventions":1878},"NCT05609682","Effect of Gabapentin on Post-Operative Pain in Minimally Invasive Sacrocolpopexy",[88],"2024-05-29","2022-11-29",[1877],"Post Operative Pain",[1866],{"trials":1880,"activeCount":101},[],{"trials":1882,"activeCount":101},[],{"trials":1884,"activeCount":101},[1885],{"nctId":1886,"briefTitle":1887,"status":532,"phases":1888,"primaryCompletion":1614,"completion":1614,"start":1889,"enrollment":97,"conditions":1890,"interventions":1893},"NCT00735124","Post-Operative Pain Scores and Analgesic Requirements After Elective Inguinal Herniorrhaphy",[90,91],"2008-11-06",[1637,1891,1892],"Analgesia","Hernia, Inguinal",[1866],{"trials":1895,"activeCount":101},[],{"trials":1897,"activeCount":101},[],{"intervention":515,"totalTrials":126,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1912,"NA":1914},{"trials":1901,"activeCount":101},[],{"trials":1903,"activeCount":101},[],{"trials":1905,"activeCount":101},[],{"trials":1907,"activeCount":101},[1908],{"nctId":507,"briefTitle":508,"status":109,"phases":1909,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":1910,"interventions":1911},[90,91],[15],[515,487],{"trials":1913,"activeCount":101},[],{"trials":1915,"activeCount":101},[],{"intervention":1917,"totalTrials":126,"cells":1918},"Ranolazine",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1935,"NA":1937},{"trials":1920,"activeCount":101},[],{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[],{"trials":1926,"activeCount":101},[1927],{"nctId":1928,"briefTitle":1929,"status":532,"phases":1930,"primaryCompletion":1931,"completion":1931,"start":1932,"enrollment":19,"conditions":1933,"interventions":1934},"NCT01349491","Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion",[91],"2014-06","2012-03",[18],[1917],{"trials":1936,"activeCount":101},[],{"trials":1938,"activeCount":101},[],{"intervention":1940,"totalTrials":126,"cells":1941},"Benzoyl peroxide",{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1948,"PHASE4":1960,"NA":1962},{"trials":1943,"activeCount":101},[],{"trials":1945,"activeCount":101},[],{"trials":1947,"activeCount":101},[],{"trials":1949,"activeCount":101},[1950],{"nctId":1951,"briefTitle":1952,"status":461,"phases":1953,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":101,"conditions":1956,"interventions":1958},"NCT05536882","MC RCT - BPO vs Adapalene",[91],"2023-10-09","2022-05-18",[1957],"Molluscum Contagiosum",[1940,1959],"Adapalene Gel",{"trials":1961,"activeCount":101},[],{"trials":1963,"activeCount":101},[],{"intervention":1959,"totalTrials":126,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":101},[],{"trials":1969,"activeCount":101},[],{"trials":1971,"activeCount":101},[],{"trials":1973,"activeCount":101},[1974],{"nctId":1951,"briefTitle":1952,"status":461,"phases":1975,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":101,"conditions":1976,"interventions":1977},[91],[1957],[1940,1959],{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":101},[],{"intervention":1983,"totalTrials":126,"cells":1984},"Acetaminophen, Ibuprofen",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":2005,"NA":2007},{"trials":1986,"activeCount":101},[],{"trials":1988,"activeCount":101},[],{"trials":1990,"activeCount":101},[],{"trials":1992,"activeCount":101},[1993],{"nctId":1994,"briefTitle":1995,"status":1996,"phases":1997,"primaryCompletion":464,"completion":1998,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2003},"NCT04423107","Assessment of Postop Hypospadias Pain","UNKNOWN",[91],"2023-01","2020-07-01",150,[2002],"Hypospadias",[1983,2004],"Acetaminophen, Ibuprofen, Oxycodone",{"trials":2006,"activeCount":101},[],{"trials":2008,"activeCount":101},[],{"intervention":2004,"totalTrials":126,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2017,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":101},[],{"trials":2014,"activeCount":101},[],{"trials":2016,"activeCount":101},[],{"trials":2018,"activeCount":101},[2019],{"nctId":1994,"briefTitle":1995,"status":1996,"phases":2020,"primaryCompletion":464,"completion":1998,"start":1999,"enrollment":2000,"conditions":2021,"interventions":2022},[91],[2002],[1983,2004],{"trials":2024,"activeCount":101},[],{"trials":2026,"activeCount":101},[],{"intervention":2028,"totalTrials":126,"cells":2029},"Fentanyl",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2036,"PHASE4":2048,"NA":2050},{"trials":2031,"activeCount":101},[],{"trials":2033,"activeCount":101},[],{"trials":2035,"activeCount":101},[],{"trials":2037,"activeCount":101},[2038],{"nctId":2039,"briefTitle":2040,"status":109,"phases":2041,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":1160,"conditions":2044,"interventions":2045},"NCT01270659","Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury",[91],"2014-10","2011-05",[1637],[2028,2028,2046,2047],"Oxycodone\u002Facetaminophen","oxycodone\u002Facetaminophen",{"trials":2049,"activeCount":101},[],{"trials":2051,"activeCount":101},[],{"intervention":2046,"totalTrials":126,"cells":2053},{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2060,"PHASE4":2066,"NA":2068},{"trials":2055,"activeCount":101},[],{"trials":2057,"activeCount":101},[],{"trials":2059,"activeCount":101},[],{"trials":2061,"activeCount":101},[2062],{"nctId":2039,"briefTitle":2040,"status":109,"phases":2063,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":1160,"conditions":2064,"interventions":2065},[91],[1637],[2028,2028,2046,2047],{"trials":2067,"activeCount":101},[],{"trials":2069,"activeCount":101},[],{"intervention":2071,"totalTrials":126,"cells":2072},"Atomoxetine",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2090,"NA":2092},{"trials":2074,"activeCount":101},[],{"trials":2076,"activeCount":101},[],{"trials":2078,"activeCount":101},[],{"trials":2080,"activeCount":101},[2081],{"nctId":2082,"briefTitle":2083,"status":109,"phases":2084,"primaryCompletion":2085,"completion":2085,"start":559,"enrollment":1229,"conditions":2086,"interventions":2089},"NCT00418262","Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD\u002FADHD",[91],"2015-04-22",[2087,2088],"Fetal Alcohol Syndrome","Attention Deficit Hyperactivity Disorder (ADHD)",[2071],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":101},[],{"intervention":2095,"totalTrials":126,"cells":2096},"Ondansetron, dexamethasone, aprepitant",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2117,"NA":2119},{"trials":2098,"activeCount":101},[],{"trials":2100,"activeCount":101},[],{"trials":2102,"activeCount":101},[],{"trials":2104,"activeCount":101},[2105],{"nctId":2106,"briefTitle":2107,"status":109,"phases":2108,"primaryCompletion":2109,"completion":2109,"start":2110,"enrollment":1100,"conditions":2111,"interventions":2115},"NCT01661335","Efficacy of Aprepitant (Emend®) in Children",[91],"2017-06-29","2012-06-01",[2112,2113,2114],"Nausea","Vomiting","Childhood Cancer",[2095,2116],"Ondansetron, Dexamethasone, placebo",{"trials":2118,"activeCount":101},[],{"trials":2120,"activeCount":101},[],{"intervention":2116,"totalTrials":126,"cells":2122},{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2129,"PHASE4":2135,"NA":2137},{"trials":2124,"activeCount":101},[],{"trials":2126,"activeCount":101},[],{"trials":2128,"activeCount":101},[],{"trials":2130,"activeCount":101},[2131],{"nctId":2106,"briefTitle":2107,"status":109,"phases":2132,"primaryCompletion":2109,"completion":2109,"start":2110,"enrollment":1100,"conditions":2133,"interventions":2134},[91],[2112,2113,2114],[2095,2116],{"trials":2136,"activeCount":101},[],{"trials":2138,"activeCount":101},[],{"intervention":2140,"totalTrials":126,"cells":2141},"4% lidocaine gel application with sham microneedle device",{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2148,"PHASE4":2161,"NA":2163},{"trials":2143,"activeCount":101},[],{"trials":2145,"activeCount":101},[],{"trials":2147,"activeCount":101},[],{"trials":2149,"activeCount":101},[2150],{"nctId":2151,"briefTitle":2152,"status":461,"phases":2153,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":101,"conditions":2156,"interventions":2159},"NCT01145326","Functional Microarray Augmentation of Skin Treatment With Lidocaine",[90,91],"2017-12","2015-01",[2157,2158],"Pain Perception","Phlebotomy",[2140,2160],"Microneedle-facilitated lidocaine application",{"trials":2162,"activeCount":101},[],{"trials":2164,"activeCount":101},[],{"intervention":2160,"totalTrials":126,"cells":2166},{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2173,"PHASE4":2179,"NA":2181},{"trials":2168,"activeCount":101},[],{"trials":2170,"activeCount":101},[],{"trials":2172,"activeCount":101},[],{"trials":2174,"activeCount":101},[2175],{"nctId":2151,"briefTitle":2152,"status":461,"phases":2176,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":101,"conditions":2177,"interventions":2178},[90,91],[2157,2158],[2140,2160],{"trials":2180,"activeCount":101},[],{"trials":2182,"activeCount":101},[],{"intervention":2184,"totalTrials":126,"cells":2185},"Omegaven",{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2192,"PHASE4":2211,"NA":2213},{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[],{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[2194],{"nctId":2195,"briefTitle":2196,"status":109,"phases":2197,"primaryCompletion":2198,"completion":2199,"start":2200,"enrollment":2201,"conditions":2202,"interventions":2210},"NCT02370251","Compassionate Use of Omegaven in Children",[90,91],"2018-09-27","2019-09-27","2015-06",63,[2203,2204,2205,2206,2207,2208,2209],"Total Parenteral Nutrition-induced Cholestasis","Cholestasis","Short Bowel Syndrome","Gastroschisis","Intestinal Atresia","Infant, Premature, Diseases","Cholestasis of Parenteral Nutrition",[2184],{"trials":2212,"activeCount":101},[],{"trials":2214,"activeCount":101},[],{"intervention":2216,"totalTrials":126,"cells":2217},"clomiphene citrate",{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2237,"NA":2239},{"trials":2219,"activeCount":101},[],{"trials":2221,"activeCount":101},[],{"trials":2223,"activeCount":101},[],{"trials":2225,"activeCount":101},[2226],{"nctId":2227,"briefTitle":2228,"status":109,"phases":2229,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":1812,"conditions":2232,"interventions":2236},"NCT01008319","Traditional Clomiphene Citrate Administration vs. Stair-step Approach",[91],"2015-11","2009-10",[2233,2234,2235],"Ovulatory Dysfunction","Anovulation","Ovulation Induction",[2216,2216],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[],{"intervention":2242,"totalTrials":126,"cells":2243},"Topiramate",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2259,"NA":2261},{"trials":2245,"activeCount":101},[],{"trials":2247,"activeCount":101},[],{"trials":2249,"activeCount":101},[],{"trials":2251,"activeCount":101},[2252],{"nctId":2253,"briefTitle":2254,"status":109,"phases":2255,"completion":558,"start":1604,"enrollment":560,"conditions":2256,"interventions":2258},"NCT00204386","Safety & Efficacy Study Using Topiramate in Posttraumatic Stress Disorder",[90,91],[2257],"Posttraumatic Stress Disorder",[2242],{"trials":2260,"activeCount":101},[],{"trials":2262,"activeCount":101},[],{"intervention":2264,"totalTrials":126,"cells":2265},"Methylphenidate Transdermal System",{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2270,"PHASE3":2272,"PHASE4":2286,"NA":2288},{"trials":2267,"activeCount":101},[],{"trials":2269,"activeCount":101},[],{"trials":2271,"activeCount":101},[],{"trials":2273,"activeCount":101},[2274],{"nctId":2275,"briefTitle":2276,"status":109,"phases":2277,"primaryCompletion":2278,"completion":2279,"start":2280,"enrollment":2281,"conditions":2282,"interventions":2285},"NCT00541346","A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms",[91],"2009-05","2010-02","2007-09",16,[2283,2284],"Autism","Attention Deficit Hyperactivity Disorder",[2264],{"trials":2287,"activeCount":101},[],{"trials":2289,"activeCount":101},[],{"intervention":468,"totalTrials":126,"cells":2291},{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2293,"activeCount":101},[],{"trials":2295,"activeCount":101},[],{"trials":2297,"activeCount":101},[2298],{"nctId":459,"briefTitle":460,"status":461,"phases":2299,"primaryCompletion":463,"completion":188,"start":464,"enrollment":101,"conditions":2300,"interventions":2301},[90],[466],[468,76],{"trials":2303,"activeCount":101},[],{"trials":2305,"activeCount":101},[],{"trials":2307,"activeCount":101},[],{"intervention":2309,"totalTrials":126,"cells":2310},"Memory XL",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2315,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":101},[],{"trials":2316,"activeCount":101},[2317],{"nctId":2318,"briefTitle":2319,"status":532,"phases":2320,"primaryCompletion":2043,"completion":2043,"start":2321,"enrollment":19,"conditions":2322,"interventions":2324},"NCT00903695","MemoryXL Effects on Mild Cognitive Impairment Patients",[90],"2009-06",[2323],"Mild Cognitive Impairment",[2309],{"trials":2326,"activeCount":101},[],{"trials":2328,"activeCount":101},[],{"trials":2330,"activeCount":101},[],{"intervention":668,"totalTrials":126,"cells":2332},{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2334,"activeCount":101},[],{"trials":2336,"activeCount":101},[],{"trials":2338,"activeCount":101},[2339],{"nctId":660,"briefTitle":661,"status":532,"phases":2340,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":2341,"interventions":2342},[90],[15],[640,668],{"trials":2344,"activeCount":101},[],{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[],{"intervention":553,"totalTrials":126,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2352,"activeCount":101},[],{"trials":2354,"activeCount":101},[],{"trials":2356,"activeCount":101},[2357],{"nctId":543,"briefTitle":544,"status":109,"phases":2358,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":2359,"interventions":2360},[90],[551,27],[553,521],{"trials":2362,"activeCount":101},[],{"trials":2364,"activeCount":101},[],{"trials":2366,"activeCount":101},[],{"intervention":565,"totalTrials":126,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2379,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":101},[],{"trials":2372,"activeCount":101},[],{"trials":2374,"activeCount":101},[2375],{"nctId":555,"briefTitle":556,"status":109,"phases":2376,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":2377,"interventions":2378},[90],[562],[564,565,566],{"trials":2380,"activeCount":101},[],{"trials":2382,"activeCount":101},[],{"trials":2384,"activeCount":101},[],{"intervention":566,"totalTrials":126,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":101},[],{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[2393],{"nctId":555,"briefTitle":556,"status":109,"phases":2394,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":2395,"interventions":2396},[90],[562],[564,565,566],{"trials":2398,"activeCount":101},[],{"trials":2400,"activeCount":101},[],{"trials":2402,"activeCount":101},[],{"intervention":1382,"totalTrials":126,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2415,"PHASE4":2417,"NA":2419},{"trials":2406,"activeCount":101},[],{"trials":2408,"activeCount":101},[],{"trials":2410,"activeCount":101},[2411],{"nctId":1372,"briefTitle":1373,"status":109,"phases":2412,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":16,"conditions":2413,"interventions":2414},[90],[1378,1379,1380],[1382,454,1383],{"trials":2416,"activeCount":101},[],{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":101},[],{"intervention":1383,"totalTrials":126,"cells":2422},{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":101},[],{"trials":2428,"activeCount":101},[2429],{"nctId":1372,"briefTitle":1373,"status":109,"phases":2430,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":16,"conditions":2431,"interventions":2432},[90],[1378,1379,1380],[1382,454,1383],{"trials":2434,"activeCount":101},[],{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[],{"intervention":579,"totalTrials":126,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":101},[],{"trials":2444,"activeCount":101},[],{"trials":2446,"activeCount":101},[2447],{"nctId":568,"briefTitle":569,"status":461,"phases":2448,"primaryCompletion":571,"completion":572,"start":573,"enrollment":101,"conditions":2449,"interventions":2450},[90],[27,575,576,577],[579,521],{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[],{"intervention":2458,"totalTrials":126,"cells":2459},"Paclitaxel, Cisplatin IP",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2461,"activeCount":101},[],{"trials":2463,"activeCount":101},[],{"trials":2465,"activeCount":101},[2466],{"nctId":2467,"briefTitle":2468,"status":532,"phases":2469,"primaryCompletion":1394,"completion":1394,"start":2470,"enrollment":2471,"conditions":2472,"interventions":2475},"NCT00582205","Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma",[90],"2006-01",21,[2473,1410,1379,2474],"Ovarian Cancer","Uterine Cancer",[2458],{"trials":2477,"activeCount":101},[],{"trials":2479,"activeCount":101},[],{"trials":2481,"activeCount":101},[],{"intervention":2483,"totalTrials":126,"cells":2484},"Cinnamon or placebo 500 mg capsule twice daily",{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2486,"activeCount":101},[],{"trials":2488,"activeCount":101},[],{"trials":2490,"activeCount":101},[2491],{"nctId":2492,"briefTitle":2493,"status":109,"phases":2494,"primaryCompletion":1376,"completion":1376,"start":1635,"enrollment":2495,"conditions":2496,"interventions":2498},"NCT00237640","Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus",[90],85,[2497],"Diabetes Mellitus, Adult Onset",[2483],{"trials":2500,"activeCount":101},[],{"trials":2502,"activeCount":101},[],{"trials":2504,"activeCount":101},[],{"intervention":2506,"totalTrials":126,"cells":2507},"Erlotinib",{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2509,"activeCount":101},[],{"trials":2511,"activeCount":101},[],{"trials":2513,"activeCount":101},[2514],{"nctId":2515,"briefTitle":2516,"status":532,"phases":2517,"primaryCompletion":2518,"completion":2519,"start":2520,"enrollment":97,"conditions":2521,"interventions":2523},"NCT01038856","Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera",[90],"2012-12","2014-02","2009-12",[2522],"Polycythemia Vera",[2506],{"trials":2525,"activeCount":101},[],{"trials":2527,"activeCount":101},[],{"trials":2529,"activeCount":101},[],{"intervention":2531,"totalTrials":126,"cells":2532},"Irinotecan, Oxaliplatin, Leucovorin, 5-FU",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2534,"activeCount":101},[],{"trials":2536,"activeCount":101},[],{"trials":2538,"activeCount":101},[2539],{"nctId":2540,"briefTitle":2541,"status":532,"phases":2542,"primaryCompletion":1836,"completion":1836,"start":2043,"enrollment":97,"conditions":2543,"interventions":2545},"NCT01359007","FOLFIRINOX in Patients With Inoperable Pancreatic Cancer",[90],[2544],"Adenocarcinoma of Pancreas",[2531],{"trials":2547,"activeCount":101},[],{"trials":2549,"activeCount":101},[],{"trials":2551,"activeCount":101},[],{"intervention":1117,"totalTrials":126,"cells":2553},{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2555,"activeCount":101},[],{"trials":2557,"activeCount":101},[],{"trials":2559,"activeCount":101},[2560],{"nctId":1107,"briefTitle":1108,"status":109,"phases":2561,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1113,"conditions":2562,"interventions":2563},[89,90],[1115],[46,1117],{"trials":2565,"activeCount":101},[],{"trials":2567,"activeCount":101},[],{"trials":2569,"activeCount":101},[],{"intervention":2571,"totalTrials":126,"cells":2572},"Nicotine replacement therapy",{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2574,"activeCount":101},[],{"trials":2576,"activeCount":101},[],{"trials":2578,"activeCount":101},[2579],{"nctId":2580,"briefTitle":2581,"status":109,"phases":2582,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":2585,"conditions":2586,"interventions":2587},"NCT05095779","Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties",[90],"2023-08-11","2022-03-09",165,[29,149],[2571],{"trials":2589,"activeCount":101},[],{"trials":2591,"activeCount":101},[],{"trials":2593,"activeCount":101},[],{"intervention":2595,"totalTrials":126,"cells":2596},"Intravitreal Aflibercept",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2598,"activeCount":101},[],{"trials":2600,"activeCount":101},[],{"trials":2602,"activeCount":101},[2603],{"nctId":2604,"briefTitle":2605,"status":109,"phases":2606,"primaryCompletion":2519,"completion":2230,"start":2607,"enrollment":2608,"conditions":2609,"interventions":2611},"NCT01805297","Aflibercept Injection for Proliferative Diabetic Retinopathy",[90],"2013-03",12,[2610],"Vitreous Hemorrhage",[2595],{"trials":2613,"activeCount":101},[],{"trials":2615,"activeCount":101},[],{"trials":2617,"activeCount":101},[],{"intervention":2619,"totalTrials":440,"cells":2620},"Caffeine",{"EARLY_PHASE1":2621,"PHASE1":2631,"PHASE2":2648,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2622,"activeCount":101},[2623],{"nctId":2624,"briefTitle":2625,"status":109,"phases":2626,"primaryCompletion":2627,"completion":2627,"start":2628,"enrollment":19,"conditions":2629,"interventions":2630},"NCT04730193","Caffeine and Cerebrovascular Reactivity",[88],"2022-08-01","2021-02-01",[2619],[2619],{"trials":2632,"activeCount":101},[2633,2641],{"nctId":2634,"briefTitle":2635,"status":532,"phases":2636,"primaryCompletion":2637,"completion":2637,"start":2638,"enrollment":440,"conditions":2639,"interventions":2640},"NCT02125643","EIMD Mechanisms Causing Force Loss",[89],"2015-05","2014-08",[24],[2619],{"nctId":2642,"briefTitle":2643,"status":109,"phases":2644,"primaryCompletion":2637,"completion":2637,"start":2645,"enrollment":610,"conditions":2646,"interventions":2647},"NCT02115763","The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial",[89],"2014-04",[24],[2619],{"trials":2649,"activeCount":101},[],{"trials":2651,"activeCount":101},[],{"trials":2653,"activeCount":101},[],{"trials":2655,"activeCount":101},[],{"intervention":2657,"totalTrials":126,"cells":2658},"mouth spray",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2671,"PHASE3":2673,"PHASE4":2675,"NA":2677},{"trials":2660,"activeCount":101},[],{"trials":2662,"activeCount":101},[2663],{"nctId":2664,"briefTitle":2665,"status":109,"phases":2666,"primaryCompletion":2667,"completion":2667,"start":1635,"enrollment":431,"conditions":2668,"interventions":2670},"NCT00595933","Comparing Over-the-counter Dry Mouth Remedies After Radiation",[89],"2010-06",[2669],"Xerostomia",[2657,2657],{"trials":2672,"activeCount":101},[],{"trials":2674,"activeCount":101},[],{"trials":2676,"activeCount":101},[],{"trials":2678,"activeCount":101},[],{"intervention":2680,"totalTrials":126,"cells":2681},"Unesbulin",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2695,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2683,"activeCount":101},[],{"trials":2685,"activeCount":101},[2686],{"nctId":2687,"briefTitle":2688,"status":109,"phases":2689,"primaryCompletion":2690,"completion":2691,"start":2692,"enrollment":1229,"conditions":2693,"interventions":2694},"NCT03206645","Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy",[89],"2021-08-11","2024-03-31","2017-08-28",[2473],[2680],{"trials":2696,"activeCount":101},[],{"trials":2698,"activeCount":101},[],{"trials":2700,"activeCount":101},[],{"trials":2702,"activeCount":101},[],{"intervention":2704,"totalTrials":126,"cells":2705},"Strattera",{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2707,"activeCount":101},[],{"trials":2709,"activeCount":101},[2710],{"nctId":2711,"briefTitle":2712,"status":109,"phases":2713,"primaryCompletion":2085,"completion":2085,"start":559,"enrollment":2714,"conditions":2715,"interventions":2718},"NCT00417794","Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD\u002FADHD",[89],38,[2087,2716,2717],"Attention Deficit Disorder With Hyperactivity (ADHD)","Attention Deficit Disorder (ADD)",[2704],{"trials":2720,"activeCount":101},[],{"trials":2722,"activeCount":101},[],{"trials":2724,"activeCount":101},[],{"trials":2726,"activeCount":101},[],{"intervention":2728,"totalTrials":126,"cells":2729},"Eribulin mesylate",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2745,"PHASE3":2747,"PHASE4":2749,"NA":2751},{"trials":2731,"activeCount":101},[],{"trials":2733,"activeCount":101},[2734],{"nctId":2735,"briefTitle":2736,"status":532,"phases":2737,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":440,"conditions":2740,"interventions":2744},"NCT02082626","Study of Eribulin in Children With Cancer to Determine Safety",[89],"2018-06","2014-02-01",[2741,2742,2743],"Pediatric Cancer","Solid Tumors","Lymphoma",[2728],{"trials":2746,"activeCount":101},[],{"trials":2748,"activeCount":101},[],{"trials":2750,"activeCount":101},[],{"trials":2752,"activeCount":101},[],{"intervention":1070,"totalTrials":126,"cells":2754},{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2763,"PHASE3":2765,"PHASE4":2767,"NA":2769},{"trials":2756,"activeCount":101},[],{"trials":2758,"activeCount":101},[2759],{"nctId":1060,"briefTitle":1061,"status":109,"phases":2760,"primaryCompletion":1063,"completion":1064,"start":1065,"enrollment":1066,"conditions":2761,"interventions":2762},[89],[1068],[1070,454,455],{"trials":2764,"activeCount":101},[],{"trials":2766,"activeCount":101},[],{"trials":2768,"activeCount":101},[],{"trials":2770,"activeCount":101},[],{"intervention":2772,"totalTrials":126,"cells":2773},"Vidaza",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2787,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2775,"activeCount":101},[],{"trials":2777,"activeCount":101},[2778],{"nctId":2779,"briefTitle":2780,"status":532,"phases":2781,"primaryCompletion":2782,"completion":2782,"start":2783,"enrollment":22,"conditions":2784,"interventions":2786},"NCT01167816","Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer",[89],"2014-01","2010-07",[2785],"Pancreatic Cancer",[2772],{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[],{"trials":2792,"activeCount":101},[],{"trials":2794,"activeCount":101},[],{"intervention":2796,"totalTrials":126,"cells":2797},"Normal Saline and 0.3% ofloxacin",{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2811,"PHASE3":2813,"PHASE4":2815,"NA":2817},{"trials":2799,"activeCount":101},[],{"trials":2801,"activeCount":101},[2802],{"nctId":2803,"briefTitle":2804,"status":461,"phases":2805,"primaryCompletion":2667,"completion":2667,"start":2806,"enrollment":101,"conditions":2807,"interventions":2809},"NCT00584155","Protection From Cisplatin Ototoxicity by Lactated Ringers",[89],"2006-07",[2808],"Hearing Loss",[2796,2810],"Lactated Ringer's with 0.03% Ofloxacin",{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":101},[],{"trials":2816,"activeCount":101},[],{"trials":2818,"activeCount":101},[],{"intervention":2810,"totalTrials":126,"cells":2820},{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2829,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2822,"activeCount":101},[],{"trials":2824,"activeCount":101},[2825],{"nctId":2803,"briefTitle":2804,"status":461,"phases":2826,"primaryCompletion":2667,"completion":2667,"start":2806,"enrollment":101,"conditions":2827,"interventions":2828},[89],[2808],[2796,2810],{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[],{"trials":2834,"activeCount":101},[],{"trials":2836,"activeCount":101},[],{"intervention":2838,"totalTrials":126,"cells":2839},"Irinotecan",{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2854,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2841,"activeCount":101},[],{"trials":2843,"activeCount":101},[2844],{"nctId":2845,"briefTitle":2846,"status":109,"phases":2847,"primaryCompletion":2848,"completion":2848,"start":2849,"enrollment":343,"conditions":2850,"interventions":2853},"NCT00222443","Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy",[89],"2007-12","2004-09",[2851,2852],"Lymphomas","Tumors",[2838],{"trials":2855,"activeCount":101},[],{"trials":2857,"activeCount":101},[],{"trials":2859,"activeCount":101},[],{"trials":2861,"activeCount":101},[],{"intervention":2863,"totalTrials":126,"cells":2864},"imiquimod",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2880,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2866,"activeCount":101},[],{"trials":2868,"activeCount":101},[2869],{"nctId":2870,"briefTitle":2871,"status":109,"phases":2872,"primaryCompletion":1603,"start":2873,"enrollment":2874,"conditions":2875,"interventions":2878},"NCT00453050","Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin",[89],"2006-03",11,[2876,2877],"Melanoma (Skin)","Metastatic Cancer",[2863,2879],"indocyanine green solution",{"trials":2881,"activeCount":101},[],{"trials":2883,"activeCount":101},[],{"trials":2885,"activeCount":101},[],{"trials":2887,"activeCount":101},[],{"intervention":2879,"totalTrials":126,"cells":2889},{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2898,"PHASE3":2900,"PHASE4":2902,"NA":2904},{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[2894],{"nctId":2870,"briefTitle":2871,"status":109,"phases":2895,"primaryCompletion":1603,"start":2873,"enrollment":2874,"conditions":2896,"interventions":2897},[89],[2876,2877],[2863,2879],{"trials":2899,"activeCount":101},[],{"trials":2901,"activeCount":101},[],{"trials":2903,"activeCount":101},[],{"trials":2905,"activeCount":101},[],{"intervention":2907,"totalTrials":126,"cells":2908},"L-Citrulline,",{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2922,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2910,"activeCount":101},[],{"trials":2912,"activeCount":101},[2913],{"nctId":2914,"briefTitle":2915,"status":109,"phases":2916,"primaryCompletion":2917,"completion":2918,"start":2919,"enrollment":16,"conditions":2920,"interventions":2921},"NCT05722860","L-Citrulline and Endothelial Function",[89],"2024-11-28","2024-12-28","2024-01-03",[193],[2907],{"trials":2923,"activeCount":101},[],{"trials":2925,"activeCount":101},[],{"trials":2927,"activeCount":101},[],{"trials":2929,"activeCount":101},[],{"intervention":2931,"totalTrials":126,"cells":2932},"Saline",{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2948,"PHASE3":2950,"PHASE4":2952,"NA":2954},{"trials":2934,"activeCount":101},[],{"trials":2936,"activeCount":101},[2937],{"nctId":2938,"briefTitle":2939,"status":109,"phases":2940,"primaryCompletion":2941,"completion":2941,"start":2942,"enrollment":2943,"conditions":2944,"interventions":2946},"NCT00584597","A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis",[89],"2010-10","2005-10",14,[2945,741],"Mucositis",[2931,2947,2947,2947],"Traumeel S",{"trials":2949,"activeCount":101},[],{"trials":2951,"activeCount":101},[],{"trials":2953,"activeCount":101},[],{"trials":2955,"activeCount":101},[],{"intervention":2947,"totalTrials":126,"cells":2957},{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2966,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2959,"activeCount":101},[],{"trials":2961,"activeCount":101},[2962],{"nctId":2938,"briefTitle":2939,"status":109,"phases":2963,"primaryCompletion":2941,"completion":2941,"start":2942,"enrollment":2943,"conditions":2964,"interventions":2965},[89],[2945,741],[2931,2947,2947,2947],{"trials":2967,"activeCount":101},[],{"trials":2969,"activeCount":101},[],{"trials":2971,"activeCount":101},[],{"trials":2973,"activeCount":101},[],{"intervention":2975,"totalTrials":126,"cells":2976},"Pyrroloquinoline quinone",{"EARLY_PHASE1":2977,"PHASE1":2987,"PHASE2":2989,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2978,"activeCount":101},[2979],{"nctId":2980,"briefTitle":2981,"status":461,"phases":2982,"primaryCompletion":2983,"completion":2983,"start":55,"enrollment":101,"conditions":2984,"interventions":2986},"NCT06245083","Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes",[88],"2025-08",[2985],"Maternal Obesity",[2975],{"trials":2988,"activeCount":101},[],{"trials":2990,"activeCount":101},[],{"trials":2992,"activeCount":101},[],{"trials":2994,"activeCount":101},[],{"trials":2996,"activeCount":101},[],{"intervention":2998,"totalTrials":126,"cells":2999},"Ibuprofen, acetaminophen, oxycodone",{"EARLY_PHASE1":3000,"PHASE1":3012,"PHASE2":3014,"PHASE3":3016,"PHASE4":3018,"NA":3020},{"trials":3001,"activeCount":101},[3002],{"nctId":3003,"briefTitle":3004,"status":109,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":3008,"conditions":3009,"interventions":3011},"NCT04612920","Towards Enhanced Recovery After Cesarean",[88],"2023-03-08","2020-12-12",33,[3010],"Cesarean Section Complications",[2998],{"trials":3013,"activeCount":101},[],{"trials":3015,"activeCount":101},[],{"trials":3017,"activeCount":101},[],{"trials":3019,"activeCount":101},[],{"trials":3021,"activeCount":101},[],{"intervention":3023,"totalTrials":126,"cells":3024},"Omeprazole",{"EARLY_PHASE1":3025,"PHASE1":3037,"PHASE2":3039,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3026,"activeCount":101},[3027],{"nctId":3028,"briefTitle":3029,"status":532,"phases":3030,"primaryCompletion":3031,"completion":3032,"start":3033,"enrollment":1700,"conditions":3034,"interventions":3036},"NCT04930991","High Dose Omeprazole in Patients With Pancreatic Cancer",[88],"2026-03-03","2026-04-03","2021-09-07",[3035],"Exocrine Pancreatic Cancer",[3023],{"trials":3038,"activeCount":101},[],{"trials":3040,"activeCount":101},[],{"trials":3042,"activeCount":101},[],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"intervention":3048,"totalTrials":126,"cells":3049},"SHINGRIX",{"EARLY_PHASE1":3050,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3051,"activeCount":101},[3052],{"nctId":3053,"briefTitle":3054,"status":109,"phases":3055,"primaryCompletion":3056,"completion":3057,"start":3058,"enrollment":3059,"conditions":3060,"interventions":3064},"NCT04523246","Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents",[88],"2021-12-30","2023-05-19","2020-09-01",217,[3061,3062,3063],"Herpes Zoster","Allergy and Immunology","Corona Virus Infection",[3048,3065],"Normal Saline",{"trials":3067,"activeCount":101},[],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[],{"trials":3073,"activeCount":101},[],{"trials":3075,"activeCount":101},[],{"intervention":3065,"totalTrials":126,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3084,"PHASE2":3086,"PHASE3":3088,"PHASE4":3090,"NA":3092},{"trials":3079,"activeCount":101},[3080],{"nctId":3053,"briefTitle":3054,"status":109,"phases":3081,"primaryCompletion":3056,"completion":3057,"start":3058,"enrollment":3059,"conditions":3082,"interventions":3083},[88],[3061,3062,3063],[3048,3065],{"trials":3085,"activeCount":101},[],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":101},[],{"intervention":3095,"totalTrials":126,"cells":3096},"PerioProtect ™= plastic tray +1.7% hydrogen peroxide",{"EARLY_PHASE1":3097,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3115,"NA":3117},{"trials":3098,"activeCount":101},[3099],{"nctId":3100,"briefTitle":3101,"status":461,"phases":3102,"primaryCompletion":3103,"completion":3104,"start":3105,"enrollment":101,"conditions":3106,"interventions":3108},"NCT05669560","Efficacy of Hydrogen Peroxide Gel on Periodontitis With Diabetes",[88],"2027-05-30","2027-06-30","2023-01-20",[3107,433],"Periodontitis",[3095],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":101},[],{"intervention":3120,"totalTrials":126,"cells":3121},"Vitamin D3",{"EARLY_PHASE1":3122,"PHASE1":3133,"PHASE2":3135,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3123,"activeCount":101},[3124],{"nctId":3125,"briefTitle":3126,"status":109,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":3130,"conditions":3131,"interventions":3132},"NCT03028519","Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer",[88],"2020-12-30","2017-01-31",81,[2473],[3120],{"trials":3134,"activeCount":101},[],{"trials":3136,"activeCount":101},[],{"trials":3138,"activeCount":101},[],{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"intervention":3144,"totalTrials":126,"cells":3145},"Kyleena Intrauterine System",{"EARLY_PHASE1":3146,"PHASE1":3158,"PHASE2":3160,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3147,"activeCount":101},[3148],{"nctId":3149,"briefTitle":3150,"status":109,"phases":3151,"primaryCompletion":3152,"completion":3152,"start":3153,"enrollment":431,"conditions":3154,"interventions":3156},"NCT03657602","Immediate Postpartum Insertion of Contraceptive Intrauterine Devices",[88],"2023-01-15","2019-12-15",[3155],"Contraception",[3144,3157],"Mirena Intrauterine System",{"trials":3159,"activeCount":101},[],{"trials":3161,"activeCount":101},[],{"trials":3163,"activeCount":101},[],{"trials":3165,"activeCount":101},[],{"trials":3167,"activeCount":101},[],{"intervention":3157,"totalTrials":126,"cells":3169},{"EARLY_PHASE1":3170,"PHASE1":3176,"PHASE2":3178,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3171,"activeCount":101},[3172],{"nctId":3149,"briefTitle":3150,"status":109,"phases":3173,"primaryCompletion":3152,"completion":3152,"start":3153,"enrollment":431,"conditions":3174,"interventions":3175},[88],[3155],[3144,3157],{"trials":3177,"activeCount":101},[],{"trials":3179,"activeCount":101},[],{"trials":3181,"activeCount":101},[],{"trials":3183,"activeCount":101},[],{"trials":3185,"activeCount":101},[],{"intervention":690,"totalTrials":126,"cells":3187},{"EARLY_PHASE1":3188,"PHASE1":3194,"PHASE2":3196,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3189,"activeCount":101},[3190],{"nctId":681,"briefTitle":682,"status":109,"phases":3191,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":3192,"interventions":3193},[88],[21,688],[690,676],{"trials":3195,"activeCount":101},[],{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[],{"intervention":3205,"totalTrials":126,"cells":3206},"Intravesical Heparin",{"EARLY_PHASE1":3207,"PHASE1":3219,"PHASE2":3221,"PHASE3":3223,"PHASE4":3225,"NA":3227},{"trials":3208,"activeCount":101},[3209],{"nctId":3210,"briefTitle":3211,"status":109,"phases":3212,"primaryCompletion":3213,"completion":3214,"start":3215,"enrollment":665,"conditions":3216,"interventions":3218},"NCT02246270","Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)",[88],"2025-12-31","2026-03-14","2017-11-28",[3217],"Recurrent Urinary Tract Infections",[3205],{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":101},[],{"trials":3226,"activeCount":101},[],{"trials":3228,"activeCount":101},[],{"intervention":3230,"totalTrials":163,"cells":3231},"Iloprost",{"EARLY_PHASE1":3232,"PHASE1":3234,"PHASE2":3247,"PHASE3":3249,"PHASE4":3251,"NA":3253},{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[3236],{"nctId":3237,"briefTitle":3238,"status":109,"phases":3239,"primaryCompletion":3240,"completion":3240,"start":3241,"enrollment":16,"conditions":3242,"interventions":3246},"NCT01274481","Iloprost Effects on Gas Exchange and Pulmonary Mechanics",[89],"2012-07","2011-03",[3243,3244,3245],"Acute Respiratory Distress Syndrome","Acute Lung Injury","Pulmonary Hypertension",[3230],{"trials":3248,"activeCount":101},[],{"trials":3250,"activeCount":101},[],{"trials":3252,"activeCount":101},[],{"trials":3254,"activeCount":101},[3255],{"nctId":3256,"briefTitle":3257,"status":109,"phases":3258,"primaryCompletion":3259,"completion":3260,"start":3261,"enrollment":19,"conditions":3262,"interventions":3264},"NCT00561223","Iloprost in Gas Exchange\u002FPulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)",[93],"2008-04","2012-10-31","2006-11",[3263,3245],"Chronic Obstructive Pulmonary Disease",[3265,3266],"iloprost Inhalation","iloprost",{"intervention":3268,"totalTrials":163,"cells":3269},"Nicotine polacrilex",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3276,"PHASE4":3278,"NA":3280},{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":101},[],{"trials":3275,"activeCount":101},[],{"trials":3277,"activeCount":101},[],{"trials":3279,"activeCount":101},[],{"trials":3281,"activeCount":101},[3282,3292],{"nctId":3283,"briefTitle":3284,"status":109,"phases":3285,"primaryCompletion":2518,"completion":2518,"start":1395,"enrollment":3286,"conditions":3287,"interventions":3289},"NCT01935713","Preliminary Investigation of Novel Methods to Reduce Children's Secondhand Smoke Exposure",[93],89,[3288],"Secondhand Smoke",[3268,3290,3291],"Electronic Cigarette","Dissolvable Tobacco Lozenge",{"nctId":3293,"briefTitle":3294,"status":109,"phases":3295,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":3298,"conditions":3299,"interventions":3300},"NCT01896518","Novel Methods to Reduce Children's Secondhand Smoke Exposure II",[93],"2014-12","2012-11",74,[3288],[3268,3301],"Tobacco lozenge",{"intervention":3303,"totalTrials":126,"cells":3304},"Betamethasone(Celestone soluspan) and Dexamethasone",{"EARLY_PHASE1":3305,"PHASE1":3307,"PHASE2":3309,"PHASE3":3311,"PHASE4":3313,"NA":3315},{"trials":3306,"activeCount":101},[],{"trials":3308,"activeCount":101},[],{"trials":3310,"activeCount":101},[],{"trials":3312,"activeCount":101},[],{"trials":3314,"activeCount":101},[],{"trials":3316,"activeCount":101},[3317],{"nctId":3318,"briefTitle":3319,"status":109,"phases":3320,"completion":3321,"start":3322,"conditions":3323,"interventions":3327},"NCT00418353","Antenatal Betamethasone Compared to Dexamethasone - \"BETACODE TRIAL\"",[93],"2005-04","2002-08",[3324,3325,3326],"Respiratory Distress Syndrome","Intraventricular Hemorrhage","Neonatal Mortality",[3303],{"intervention":3329,"totalTrials":126,"cells":3330},"Local Anesthesia",{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3335,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3332,"activeCount":101},[],{"trials":3334,"activeCount":101},[],{"trials":3336,"activeCount":101},[],{"trials":3338,"activeCount":101},[],{"trials":3340,"activeCount":101},[],{"trials":3342,"activeCount":101},[3343],{"nctId":3344,"briefTitle":3345,"status":109,"phases":3346,"primaryCompletion":2043,"completion":2043,"start":1741,"enrollment":3347,"conditions":3348,"interventions":3350},"NCT00583011","Local Anesthesia and Pain Perception During an Amniocentesis",[93],76,[3349],"Pregnancy",[3329],{"intervention":3352,"totalTrials":126,"cells":3353},"BIS 40",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":101},[],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[3366],{"nctId":3367,"briefTitle":3368,"status":109,"phases":3369,"primaryCompletion":3370,"completion":3370,"start":2873,"enrollment":3371,"conditions":3372,"interventions":3375},"NCT00584324","Depth of Anesthesia on Implicit Memory",[93],"2012-01",70,[3373,3374],"Anesthesia, General","Memory",[3352,3376],"BIS 60",{"intervention":3376,"totalTrials":126,"cells":3378},{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3387,"NA":3389},{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"trials":3384,"activeCount":101},[],{"trials":3386,"activeCount":101},[],{"trials":3388,"activeCount":101},[],{"trials":3390,"activeCount":101},[3391],{"nctId":3367,"briefTitle":3368,"status":109,"phases":3392,"primaryCompletion":3370,"completion":3370,"start":2873,"enrollment":3371,"conditions":3393,"interventions":3394},[93],[3373,3374],[3352,3376],{"intervention":3396,"totalTrials":126,"cells":3397},"Tocilizumab",{"EARLY_PHASE1":3398,"PHASE1":3400,"PHASE2":3402,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3399,"activeCount":101},[],{"trials":3401,"activeCount":101},[],{"trials":3403,"activeCount":101},[],{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"trials":3409,"activeCount":101},[3410],{"nctId":3411,"briefTitle":3412,"status":3413,"phases":3414,"primaryCompletion":2941,"completion":2941,"start":3415,"conditions":3416,"interventions":3418},"NCT00862758","Request for Single Patient IND for Compassionate\u002FEmergency Use of Tocilizumab","NO_LONGER_AVAILABLE",[],"2009-02",[3417],"Juvenile Idiopathic Arthritis",[3396],{"intervention":3420,"totalTrials":126,"cells":3421},"tranexamic acid",{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3428,"PHASE4":3430,"NA":3432},{"trials":3423,"activeCount":101},[],{"trials":3425,"activeCount":101},[],{"trials":3427,"activeCount":101},[],{"trials":3429,"activeCount":101},[],{"trials":3431,"activeCount":101},[],{"trials":3433,"activeCount":101},[3434],{"nctId":3435,"briefTitle":3436,"status":461,"phases":3437,"completion":3438,"start":3439,"enrollment":101,"conditions":3440,"interventions":3442},"NCT01005147","Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding",[93],"2011-10","2009-11",[3441],"Gastrointestinal Hemorrhage",[3420],{"intervention":3444,"totalTrials":126,"cells":3445},"Normal saline:",{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3452,"PHASE4":3454,"NA":3456},{"trials":3447,"activeCount":101},[],{"trials":3449,"activeCount":101},[],{"trials":3451,"activeCount":101},[],{"trials":3453,"activeCount":101},[],{"trials":3455,"activeCount":101},[],{"trials":3457,"activeCount":101},[3458],{"nctId":3459,"briefTitle":3460,"status":109,"phases":3461,"primaryCompletion":3462,"completion":3462,"start":3463,"enrollment":3008,"conditions":3464,"interventions":3466},"NCT00671723","Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients",[93],"2008-07","2006-10",[3465],"Atelectasis",[3444,3467,3468],"Hypertonic Saline","Dornase alpha",{"intervention":3467,"totalTrials":126,"cells":3470},{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3475,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3472,"activeCount":101},[],{"trials":3474,"activeCount":101},[],{"trials":3476,"activeCount":101},[],{"trials":3478,"activeCount":101},[],{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[3483],{"nctId":3459,"briefTitle":3460,"status":109,"phases":3484,"primaryCompletion":3462,"completion":3462,"start":3463,"enrollment":3008,"conditions":3485,"interventions":3486},[93],[3465],[3444,3467,3468],{"intervention":3468,"totalTrials":126,"cells":3488},{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3495,"PHASE4":3497,"NA":3499},{"trials":3490,"activeCount":101},[],{"trials":3492,"activeCount":101},[],{"trials":3494,"activeCount":101},[],{"trials":3496,"activeCount":101},[],{"trials":3498,"activeCount":101},[],{"trials":3500,"activeCount":101},[3501],{"nctId":3459,"briefTitle":3460,"status":109,"phases":3502,"primaryCompletion":3462,"completion":3462,"start":3463,"enrollment":3008,"conditions":3503,"interventions":3504},[93],[3465],[3444,3467,3468],{"intervention":3506,"totalTrials":126,"cells":3507},"iNO",{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3509,"activeCount":101},[],{"trials":3511,"activeCount":101},[],{"trials":3513,"activeCount":101},[],{"trials":3515,"activeCount":101},[],{"trials":3517,"activeCount":101},[],{"trials":3519,"activeCount":101},[3520],{"nctId":3521,"briefTitle":3522,"status":109,"phases":3523,"primaryCompletion":3524,"completion":3525,"start":3526,"enrollment":3008,"conditions":3527,"interventions":3530},"NCT01220687","Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation",[93],"2017-01","2017-05-01","2011-04",[3528,3529],"Respiratory Distress Syndrome in Premature Infants","Very Low Birth Weight Baby",[3506],{"intervention":3532,"totalTrials":126,"cells":3533},"Regular Insulin",{"EARLY_PHASE1":3534,"PHASE1":3536,"PHASE2":3538,"PHASE3":3540,"PHASE4":3542,"NA":3544},{"trials":3535,"activeCount":101},[],{"trials":3537,"activeCount":101},[],{"trials":3539,"activeCount":101},[],{"trials":3541,"activeCount":101},[],{"trials":3543,"activeCount":101},[],{"trials":3545,"activeCount":101},[3546],{"nctId":3547,"briefTitle":3548,"status":532,"phases":3549,"primaryCompletion":2278,"completion":2278,"start":3550,"enrollment":2874,"conditions":3551,"interventions":3554},"NCT00582036","Glucose Control In Hematopoetic Stem Cell Transplant",[93],"2007-02",[3552,3553],"Hyperglycemia","Hematopoietic Stem Cell Transplantation",[3532],{"intervention":3556,"totalTrials":126,"cells":3557},"Acamprosate",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3564,"PHASE4":3566,"NA":3568},{"trials":3559,"activeCount":101},[],{"trials":3561,"activeCount":101},[],{"trials":3563,"activeCount":101},[],{"trials":3565,"activeCount":101},[],{"trials":3567,"activeCount":101},[],{"trials":3569,"activeCount":101},[3570],{"nctId":3571,"briefTitle":3572,"status":532,"phases":3573,"primaryCompletion":2520,"completion":2520,"start":3550,"enrollment":3574,"conditions":3575,"interventions":3577},"NCT00425711","Study of Acamprosate in Driving Under the Influence (DUI) Court Participants",[93],4,[3576],"Alcohol Dependence",[3556],{"intervention":3290,"totalTrials":126,"cells":3579},{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3581,"activeCount":101},[],{"trials":3583,"activeCount":101},[],{"trials":3585,"activeCount":101},[],{"trials":3587,"activeCount":101},[],{"trials":3589,"activeCount":101},[],{"trials":3591,"activeCount":101},[3592],{"nctId":3283,"briefTitle":3284,"status":109,"phases":3593,"primaryCompletion":2518,"completion":2518,"start":1395,"enrollment":3286,"conditions":3594,"interventions":3595},[93],[3288],[3268,3290,3291],{"intervention":3291,"totalTrials":126,"cells":3597},{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3599,"activeCount":101},[],{"trials":3601,"activeCount":101},[],{"trials":3603,"activeCount":101},[],{"trials":3605,"activeCount":101},[],{"trials":3607,"activeCount":101},[],{"trials":3609,"activeCount":101},[3610],{"nctId":3283,"briefTitle":3284,"status":109,"phases":3611,"primaryCompletion":2518,"completion":2518,"start":1395,"enrollment":3286,"conditions":3612,"interventions":3613},[93],[3288],[3268,3290,3291],{"intervention":3615,"totalTrials":126,"cells":3616},"Norethindrone acetate and ethinyl estradiol tablets, USP",{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3623,"PHASE4":3625,"NA":3627},{"trials":3618,"activeCount":101},[],{"trials":3620,"activeCount":101},[],{"trials":3622,"activeCount":101},[],{"trials":3624,"activeCount":101},[],{"trials":3626,"activeCount":101},[],{"trials":3628,"activeCount":101},[3629],{"nctId":3630,"briefTitle":3631,"status":461,"phases":3632,"primaryCompletion":3438,"completion":3438,"start":2231,"enrollment":101,"conditions":3633,"interventions":3635},"NCT00999479","Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation",[93],[3634],"Endometrioma",[3615,3636],"ferrous fumarate (placebo)",{"intervention":3636,"totalTrials":126,"cells":3638},{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3640,"activeCount":101},[],{"trials":3642,"activeCount":101},[],{"trials":3644,"activeCount":101},[],{"trials":3646,"activeCount":101},[],{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[3651],{"nctId":3630,"briefTitle":3631,"status":461,"phases":3652,"primaryCompletion":3438,"completion":3438,"start":2231,"enrollment":101,"conditions":3653,"interventions":3654},[93],[3634],[3615,3636],{"intervention":3656,"totalTrials":126,"cells":3657},"Daptomycin",{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3662,"PHASE3":3664,"PHASE4":3666,"NA":3668},{"trials":3659,"activeCount":101},[],{"trials":3661,"activeCount":101},[],{"trials":3663,"activeCount":101},[],{"trials":3665,"activeCount":101},[],{"trials":3667,"activeCount":101},[],{"trials":3669,"activeCount":101},[3670],{"nctId":3671,"briefTitle":3672,"status":109,"phases":3673,"primaryCompletion":2645,"completion":2645,"start":3439,"enrollment":35,"conditions":3674,"interventions":3677},"NCT01012089","Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease",[93],[3675,3676],"Chronic Kidney Disease","Bacterial Infection",[3656],{"intervention":3679,"totalTrials":126,"cells":3680},"Sevoflurane group",{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3685,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3682,"activeCount":101},[],{"trials":3684,"activeCount":101},[],{"trials":3686,"activeCount":101},[],{"trials":3688,"activeCount":101},[],{"trials":3690,"activeCount":101},[],{"trials":3692,"activeCount":101},[3693],{"nctId":3694,"briefTitle":3695,"status":109,"phases":3696,"primaryCompletion":2941,"completion":2941,"start":3697,"enrollment":3698,"conditions":3699,"interventions":3701},"NCT00717574","Addition of Nitrous Oxide and Its Effects on Depth of Anesthesia",[93],"2008-03",32,[3700,3373],"Deep Sedation",[3679,3702],"Propofol group",{"intervention":3702,"totalTrials":126,"cells":3704},{"EARLY_PHASE1":3705,"PHASE1":3707,"PHASE2":3709,"PHASE3":3711,"PHASE4":3713,"NA":3715},{"trials":3706,"activeCount":101},[],{"trials":3708,"activeCount":101},[],{"trials":3710,"activeCount":101},[],{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[3717],{"nctId":3694,"briefTitle":3695,"status":109,"phases":3718,"primaryCompletion":2941,"completion":2941,"start":3697,"enrollment":3698,"conditions":3719,"interventions":3720},[93],[3700,3373],[3679,3702],{"intervention":3722,"totalTrials":126,"cells":3723},"Clopidogrel",{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3730,"PHASE4":3732,"NA":3734},{"trials":3725,"activeCount":101},[],{"trials":3727,"activeCount":101},[],{"trials":3729,"activeCount":101},[],{"trials":3731,"activeCount":101},[],{"trials":3733,"activeCount":101},[],{"trials":3735,"activeCount":101},[3736],{"nctId":3737,"briefTitle":3738,"status":109,"phases":3739,"primaryCompletion":1742,"completion":1742,"start":3740,"enrollment":1229,"conditions":3741,"interventions":3743},"NCT00644657","The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization",[93],"2007-03",[1702,3742],"Chest Pain",[3722],{"intervention":3301,"totalTrials":126,"cells":3745},{"EARLY_PHASE1":3746,"PHASE1":3748,"PHASE2":3750,"PHASE3":3752,"PHASE4":3754,"NA":3756},{"trials":3747,"activeCount":101},[],{"trials":3749,"activeCount":101},[],{"trials":3751,"activeCount":101},[],{"trials":3753,"activeCount":101},[],{"trials":3755,"activeCount":101},[],{"trials":3757,"activeCount":101},[3758],{"nctId":3293,"briefTitle":3294,"status":109,"phases":3759,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":3298,"conditions":3760,"interventions":3761},[93],[3288],[3268,3301],{"intervention":3763,"totalTrials":126,"cells":3764},"Administration of sitagliptin",{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3771,"PHASE4":3773,"NA":3775},{"trials":3766,"activeCount":101},[],{"trials":3768,"activeCount":101},[],{"trials":3770,"activeCount":101},[],{"trials":3772,"activeCount":101},[],{"trials":3774,"activeCount":101},[],{"trials":3776,"activeCount":101},[3777],{"nctId":3778,"briefTitle":3779,"status":109,"phases":3780,"primaryCompletion":3781,"completion":3781,"start":1743,"enrollment":2281,"conditions":3782,"interventions":3785},"NCT00466518","Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant",[93],"2011-01",[3783,3784],"Kidney Transplant","Type 2 Diabetes",[3763],{"intervention":3787,"totalTrials":126,"cells":3788},"Intramuscular Progesterone",{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3793,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3790,"activeCount":101},[],{"trials":3792,"activeCount":101},[],{"trials":3794,"activeCount":101},[],{"trials":3796,"activeCount":101},[],{"trials":3798,"activeCount":101},[],{"trials":3800,"activeCount":101},[3801],{"nctId":3802,"briefTitle":3803,"status":109,"phases":3804,"primaryCompletion":2043,"completion":2043,"start":3463,"enrollment":3805,"conditions":3806,"interventions":3809},"NCT00579553","Comparing IM vs. Vaginal Progesterone for Pre-term Birth",[93],174,[3807,3808],"Infant, Premature","Premature Birth",[3787,3810],"Vaginal Progesterone",{"intervention":3810,"totalTrials":126,"cells":3812},{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3819,"PHASE4":3821,"NA":3823},{"trials":3814,"activeCount":101},[],{"trials":3816,"activeCount":101},[],{"trials":3818,"activeCount":101},[],{"trials":3820,"activeCount":101},[],{"trials":3822,"activeCount":101},[],{"trials":3824,"activeCount":101},[3825],{"nctId":3802,"briefTitle":3803,"status":109,"phases":3826,"primaryCompletion":2043,"completion":2043,"start":3463,"enrollment":3805,"conditions":3827,"interventions":3828},[93],[3807,3808],[3787,3810],{"intervention":3830,"totalTrials":126,"cells":3831},"atorvastatin",{"EARLY_PHASE1":3832,"PHASE1":3834,"PHASE2":3836,"PHASE3":3838,"PHASE4":3840,"NA":3842},{"trials":3833,"activeCount":101},[],{"trials":3835,"activeCount":101},[],{"trials":3837,"activeCount":101},[],{"trials":3839,"activeCount":101},[],{"trials":3841,"activeCount":101},[],{"trials":3843,"activeCount":101},[3844],{"nctId":3845,"briefTitle":3846,"status":532,"phases":3847,"primaryCompletion":3848,"completion":3848,"start":3849,"enrollment":2471,"conditions":3850,"interventions":3852},"NCT01071993","Efficacy of Statins In Prevention of CIN",[93],"2013-07","2010-03",[3851],"Nephropathy",[3830],{"intervention":3854,"totalTrials":126,"cells":3855},"Metoprolol",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3862,"PHASE4":3864,"NA":3866},{"trials":3857,"activeCount":101},[],{"trials":3859,"activeCount":101},[],{"trials":3861,"activeCount":101},[],{"trials":3863,"activeCount":101},[],{"trials":3865,"activeCount":101},[],{"trials":3867,"activeCount":101},[3868],{"nctId":3869,"briefTitle":3870,"status":109,"phases":3871,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":1160,"conditions":3874,"interventions":3876},"NCT00756236","A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement",[93],"2015-09-02","2008-10",[3875],"Myocardial Ischemia",[3854,3877,3878],"Esmolol","P-Group",{"intervention":3877,"totalTrials":126,"cells":3880},{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3887,"PHASE4":3889,"NA":3891},{"trials":3882,"activeCount":101},[],{"trials":3884,"activeCount":101},[],{"trials":3886,"activeCount":101},[],{"trials":3888,"activeCount":101},[],{"trials":3890,"activeCount":101},[],{"trials":3892,"activeCount":101},[3893],{"nctId":3869,"briefTitle":3870,"status":109,"phases":3894,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":1160,"conditions":3895,"interventions":3896},[93],[3875],[3854,3877,3878],{"intervention":3878,"totalTrials":126,"cells":3898},{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3903,"PHASE3":3905,"PHASE4":3907,"NA":3909},{"trials":3900,"activeCount":101},[],{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[],{"trials":3906,"activeCount":101},[],{"trials":3908,"activeCount":101},[],{"trials":3910,"activeCount":101},[3911],{"nctId":3869,"briefTitle":3870,"status":109,"phases":3912,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":1160,"conditions":3913,"interventions":3914},[93],[3875],[3854,3877,3878],{"intervention":3916,"totalTrials":126,"cells":3917},"Simvastatin",{"EARLY_PHASE1":3918,"PHASE1":3920,"PHASE2":3922,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3919,"activeCount":101},[],{"trials":3921,"activeCount":101},[],{"trials":3923,"activeCount":101},[],{"trials":3925,"activeCount":101},[],{"trials":3927,"activeCount":101},[],{"trials":3929,"activeCount":101},[3930],{"nctId":3931,"briefTitle":3932,"status":461,"phases":3933,"primaryCompletion":3438,"completion":3438,"start":2941,"enrollment":101,"conditions":3934,"interventions":3936},"NCT01195428","Simvastatin Effect on the Incidence of Acute Lung Injury\u002FAdult Respiratory Distress Syndrome (ALI\u002FARDS)",[93],[3935,3244],"Adult Respiratory Distress Syndrome",[3916],{"intervention":3265,"totalTrials":126,"cells":3938},{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3943,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3940,"activeCount":101},[],{"trials":3942,"activeCount":101},[],{"trials":3944,"activeCount":101},[],{"trials":3946,"activeCount":101},[],{"trials":3948,"activeCount":101},[],{"trials":3950,"activeCount":101},[3951],{"nctId":3256,"briefTitle":3257,"status":109,"phases":3952,"primaryCompletion":3259,"completion":3260,"start":3261,"enrollment":19,"conditions":3953,"interventions":3954},[93],[3263,3245],[3265,3266],{"intervention":3956,"totalTrials":126,"cells":3957},"Cervidil 10 MG Vaginal Insert",{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3962,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3959,"activeCount":101},[],{"trials":3961,"activeCount":101},[],{"trials":3963,"activeCount":101},[],{"trials":3965,"activeCount":101},[],{"trials":3967,"activeCount":101},[],{"trials":3969,"activeCount":101},[3970],{"nctId":3971,"briefTitle":3972,"status":109,"phases":3973,"primaryCompletion":3974,"completion":3975,"start":3976,"enrollment":317,"conditions":3977,"interventions":3980},"NCT03111316","Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening",[93],"2018-01-05","2020-07-24","2017-04-09",[3978,3979],"Cervical Ripening","Induction of Labor",[3956],{"intervention":3982,"totalTrials":126,"cells":3983},"Golytely (polyethylene glycol electrolyte lavage solution) and placebo",{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":3988,"PHASE3":3990,"PHASE4":3992,"NA":3994},{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[],{"trials":3989,"activeCount":101},[],{"trials":3991,"activeCount":101},[],{"trials":3993,"activeCount":101},[],{"trials":3995,"activeCount":101},[3996],{"nctId":3997,"briefTitle":3998,"status":109,"phases":3999,"primaryCompletion":4000,"completion":4000,"start":3438,"enrollment":4001,"conditions":4002,"interventions":4003},"NCT01533688","Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients",[93],"2016-10",212,[433],[3982,4004,4005],"split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo","split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl",{"intervention":4004,"totalTrials":126,"cells":4007},{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4012,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":4009,"activeCount":101},[],{"trials":4011,"activeCount":101},[],{"trials":4013,"activeCount":101},[],{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":101},[],{"trials":4019,"activeCount":101},[4020],{"nctId":3997,"briefTitle":3998,"status":109,"phases":4021,"primaryCompletion":4000,"completion":4000,"start":3438,"enrollment":4001,"conditions":4022,"interventions":4023},[93],[433],[3982,4004,4005],{"intervention":4005,"totalTrials":126,"cells":4025},{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4027,"activeCount":101},[],{"trials":4029,"activeCount":101},[],{"trials":4031,"activeCount":101},[],{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[],{"trials":4037,"activeCount":101},[4038],{"nctId":3997,"briefTitle":3998,"status":109,"phases":4039,"primaryCompletion":4000,"completion":4000,"start":3438,"enrollment":4001,"conditions":4040,"interventions":4041},[93],[433],[3982,4004,4005],{"intervention":4043,"totalTrials":126,"cells":4044},"Busulfex, Fludarabine, ALemtuzumab",{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4051,"PHASE4":4053,"NA":4055},{"trials":4046,"activeCount":101},[],{"trials":4048,"activeCount":101},[],{"trials":4050,"activeCount":101},[],{"trials":4052,"activeCount":101},[],{"trials":4054,"activeCount":101},[],{"trials":4056,"activeCount":101},[4057],{"nctId":4058,"briefTitle":4059,"status":109,"phases":4060,"primaryCompletion":3697,"completion":3697,"start":4061,"enrollment":9,"conditions":4062,"interventions":4064},"NCT00582894","Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases",[93],"2005-02",[4063,3553],"Hematological Neoplasms",[4043],{"intervention":4066,"totalTrials":126,"cells":4067},"Triamcinolone acetonide",{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4072,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4069,"activeCount":101},[],{"trials":4071,"activeCount":101},[],{"trials":4073,"activeCount":101},[],{"trials":4075,"activeCount":101},[],{"trials":4077,"activeCount":101},[],{"trials":4079,"activeCount":101},[4080],{"nctId":4081,"briefTitle":4082,"status":109,"phases":4083,"primaryCompletion":4084,"completion":4084,"start":4085,"enrollment":2874,"conditions":4086,"interventions":4088},"NCT00229931","Triamcinolone vs. Laser for Diabetic Macular Edema",[93],"2013-05","2005-11",[4087],"DIABETIC MACULAR EDEMA",[4066]]